📘 Core Modules 1–6 🔒 Extended 7–12 ★ Gap Topics 13–17 🔀 Differentials 💎 Board Pearls ⚡ Fast Review 🚨 Emergencies
PANCE · PANRE · Board Prep Intensive

Pulmonary Medicine
Bootcamp Syllabus

Complete Pulmonary Medicine Bootcamp Syllabus — 17 clinical topics covering all PANCE pulmonary domains. Now expanded with Module D: Must-Know Differentials (7 high-yield diagnostic frameworks) and Module E: Board Pearls (domain-organized clinical decision points). Board questions available in the companion document.

17Clinical Topics
7Must-Know Differentials
6Core Modules Taught Live
10Rapid Fire Pearls
10Don't Miss Emergencies
Rajiv Choudhary, MD, MPH
Tier Key:
Tier 1 — Must Know
Tier 2 — Important
Tier 3 — Lower yield
★ = Gap topic added
Modules 1–6 · Taught Live · Open Access
Core Pulmonary Curriculum
Before you beginAsthma3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · Medium · Asthma · Diagnostic Confirmation
A 25-year-old woman reports episodic wheezing, chest tightness, and cough that consistently worsen at night and after exercise. Her physical examination between episodes is normal. What is the best initial diagnostic test?
Click to Reveal Answer
Correct answer: C — Spirometry with pre- and post-bronchodilator testing
Asthma is diagnosed by demonstrating variable expiratory airflow limitation. Spirometry establishes obstruction (reduced FEV1/FVC) and then documents reversibility after a bronchodilator — an improvement of ≥12% AND ≥200 mL in FEV1. Both thresholds must be met. This single test delivers the obstruction and the variability that together define the disease.
Why the other choices are wrong
  • Chest radiograph — Incorrect. The chest film is typically normal in asthma. It is obtained to exclude alternative diagnoses — pneumonia, foreign body, heart failure, mass — not to establish asthma.
  • Methacholine challenge testing — Incorrect. Bronchoprovocation is reserved for the patient whose spirometry is normal but whose clinical suspicion remains high. Its strength is a high negative predictive value, so a negative test largely excludes asthma. It is a second-line test, not a first one.
  • Two weeks of home peak flow monitoring — Incorrect. Peak flow is effort-dependent and insensitive, which makes it a reasonable monitoring tool for an established asthmatic tracking control, but a poor diagnostic instrument.
  • Fractional exhaled nitric oxide (FeNO) measurement — Incorrect. FeNO reflects type 2 airway inflammation and can support a diagnosis or predict inhaled corticosteroid responsiveness, but it neither establishes obstruction nor demonstrates variability, and normal values do not exclude asthma.
Board pearlMemorise the reversibility threshold as a pair: ≥12% and ≥200 mL improvement in FEV1. A percentage alone is a trap, because a 12% rise off a tiny baseline can be noise. And remember that normal spirometry does not exclude asthma — the obstruction is by definition variable, so a patient tested on a good day looks normal. That is precisely when the methacholine challenge earns its place.
Covered below under Module 1 — Asthma
Question 2 of 3 · High Yield · Asthma · GINA Track 1 Reliever
A 28-year-old woman with asthma reports symptoms roughly twice per week and no nighttime awakenings. She has never used a controller inhaler. According to the GINA Track 1 approach, what is the preferred regimen?
Click to Reveal Answer
Correct answer: B — As-needed low-dose ICS-formoterol
GINA Track 1 is the preferred pathway at every step for adults and adolescents, using low-dose ICS-formoterol as an anti-inflammatory reliever (AIR). The governing principle is that every patient with asthma receives ICS-containing therapy, because airway inflammation is present even when symptoms are infrequent. Compared with SABA-reliever regimens, as-needed ICS-formoterol substantially reduces severe exacerbations and systemic corticosteroid exposure.
Why the other choices are wrong
  • Inhaled albuterol as needed alone — Incorrect. SABA monotherapy is not supported at any step. It leaves inflammation untreated and is associated with more exacerbations, worse lung function, and increased asthma-related death. This is the single most important change in modern asthma care.
  • Daily medium-dose ICS-LABA plus as-needed albuterol — Incorrect. This is substantial overtreatment. Daily medium-dose ICS-LABA corresponds to a much higher step, appropriate for a patient with frequent symptoms or recent exacerbations — not someone symptomatic twice weekly.
  • As-needed combination ICS-albuterol (ICS-SABA) — Incorrect, though this is the closest wrong answer. As-needed ICS-SABA is a legitimate Track 2 option available from Step 1 onward, and it is genuinely correct medicine when ICS-formoterol is unavailable or not tolerated. But Track 2 is explicitly the alternative track; the question asks for the preferred regimen.
  • Daily montelukast plus as-needed albuterol — Incorrect. Leukotriene receptor antagonists are less effective than ICS for asthma control and carry an FDA boxed warning for serious neuropsychiatric events. Montelukast is an alternative or add-on, never the preferred first-line controller.
Board pearlTwo tracks, one preference. Track 1 = ICS-formoterol as anti-inflammatory reliever, preferred at all steps. Track 2 = ICS-SABA or SABA reliever, the alternative. Note the pharmacologic constraint that makes Track 1 possible: only formoterol has a rapid enough onset to serve as a reliever. Salmeterol cannot — never use an ICS-salmeterol inhaler as a rescue medication.
Covered below under Module 1 — Asthma
Question 3 of 3 · High Yield · Asthma · The Normalizing PaCO₂ Trap
A 24-year-old man with asthma presents in severe exacerbation. On arrival: respiratory rate 32, diffuse wheezing, PaCO₂ 27 mmHg. After one hour of continuous nebulized albuterol-ipratropium and IV methylprednisolone, he is drowsy, his chest is quiet on auscultation, respiratory rate is 22, PaCO₂ is 42 mmHg, and SpO₂ is 90% on 6 L. What is the most appropriate next step?
Click to Reveal Answer
Correct answer: D — Prepare for endotracheal intubation and transfer to the ICU
A normalizing PaCO₂ in acute severe asthma is a danger sign, not improvement. Early in an exacerbation, hyperventilation drives PaCO₂ down, producing the expected respiratory alkalosis. A rise back toward — or into — the normal range means the patient can no longer sustain the work of breathing. Combined with drowsiness and a quiet chest, this is impending respiratory failure and demands airway control in an ICU setting.
Why the other choices are wrong
  • Continue current therapy and repeat an arterial blood gas in two hours — Incorrect, and this is the trap the question is built around. Reading PaCO₂ 42 as “normalized” and therefore reassuring inverts its meaning. In a fatiguing asthmatic, normal is ominous, and two hours is far longer than this patient has.
  • Administer IV magnesium sulfate and reassess in one hour — Incorrect. IV magnesium is a reasonable adjunct earlier in a severe exacerbation, and he may well have warranted it in the first hour. Once ventilatory failure with depressed consciousness is established, adjunctive bronchodilation is no longer the priority.
  • Begin a trial of noninvasive positive pressure ventilation on the medical floor — Incorrect on two counts. Evidence for NIV in acute asthma is far weaker than in COPD, and depressed mental status means he cannot protect his airway — a contraindication. A general floor is also the wrong setting for a patient this unstable.
  • Discharge on a prednisone taper once the wheezing has resolved — Incorrect and dangerous. A quiet chest reflects minimal airflow, not resolved bronchospasm — wheezing requires air movement to generate. Loss of wheeze in a deteriorating asthmatic is a terminal sign.
Board pearlIn asthma, the PaCO₂ trajectory matters more than the absolute value. Expected early: low PaCO₂ with respiratory alkalosis. Ominous: normal or rising PaCO₂ in a tiring patient. The clinical companions of that gas are the ones to recognize instantly — drowsiness, inability to speak in full sentences, a silent chest, and peak flow below 25–30% of predicted. Any of these turns a nebulizer problem into an airway problem.
Covered below under Module 1 — Asthma
Tier 1
Domain 1 · Highest PANCE Weight
Module 1
Asthma
👁 Free Preview
GINA 2024 · ICS-Formoterol · SABA Paradigm Shift · Exacerbation Management
★★★ PANCE PriorityGINA 2024 Updated
Why the PANCE Tests This

Asthma is the most common chronic lung disease in the US (~8% of adults). Boards test: reversible vs irreversible obstruction, the SABA-alone paradigm shift, LABA monotherapy contraindication, exacerbation management, and the silent chest danger sign.

Core Recognition & Diagnosis
  • Episodic: Wheeze, chest tightness, cough (especially nocturnal), dyspnea — triggered by allergens, exercise, cold air, irritants
  • Spirometry: Obstructive pattern (FEV1/FVC <0.70 or below LLN) with reversibility ≥12% AND ≥200 mL improvement in FEV1 after bronchodilator
  • Normal spirometry ≠ no asthma — if clinical suspicion high, order methacholine challenge (positive = ≥20% decline in FEV1 at ≤4 mg/mL)
  • Peak flow variability >10% diurnal variation supports diagnosis
GINA 2024 Stepwise Management — The Paradigm Shift
⚑ Major Paradigm Shift — SABA-Only is No Longer Recommended
  • ALL asthma patients need ICS-containing therapy — even mild/intermittent. SABA-only treatment is no longer recommended at any GINA step.
  • As-needed ICS-formoterol reduces exacerbations by ≥60% vs SABA alone
  • LABA monotherapy (without ICS) is CONTRAINDICATED in asthma — increases risk of asthma-related death. LABAs must ALWAYS be combined with ICS.
GINA StepSeverityTrack 1 (Preferred) — ICS-FormoterolTrack 2 (Alternative) — SABA Reliever
Steps 1–2MildAs-needed low-dose ICS-formoterol ONLY (no daily controller)ICS taken whenever SABA used (Step 1); daily low-dose ICS + PRN SABA (Step 2)
Step 3ModerateLow-dose ICS-formoterol MART (maintenance AND reliever)Low-dose ICS-LABA + PRN SABA
Step 4Moderate-severeMedium-dose ICS-formoterol MARTMedium-dose ICS-LABA + PRN SABA
Step 5SevereHigh-dose ICS-formoterol MART + add-on: LAMA, biologics (dupilumab, mepolizumab), azithromycinHigh-dose ICS-LABA + LAMA + PRN SABA; consider biologics
Acute Exacerbation Management
SeverityKey FeaturesTreatment
Mild-ModerateSpO₂ >92%, able to speak sentencesSABA MDI + spacer or nebulizer q20min × 3; oral prednisone 40–50mg × 5 days (no taper ≤7 days); ipratropium for moderate exacerbations
SevereSpO₂ <92%, unable to speak full sentences, accessory muscle useContinuous nebulized albuterol + ipratropium; IV methylprednisolone; IV magnesium sulfate 2g IV over 20 min (for severe not responding); O₂ to maintain SpO₂ 93–95%
Life-ThreateningSilent chest, cyanosis, exhaustion, altered consciousness, PaCO₂ risingPrepare for intubation; all of above; call ICU; allow permissive hypercapnia on mechanical ventilation
⚑ Board Traps — Asthma
  • Silent chest in acute asthma = impending respiratory failure — no air movement. This is MORE dangerous than audible wheezing, not better.
  • Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue and impending arrest — asthmatic patients should be hyperventilating (low PaCO₂). A "normal" PaCO₂ of 40 in a severe exacerbation is a red flag.
  • Do NOT sedate the agitated asthmatic — agitation = hypoxia, not anxiety. Sedation removes the respiratory drive.
  • Heliox (helium-oxygen mixture): May be considered for severe refractory exacerbation to reduce airway resistance — reduces work of breathing.
  • Asthma + NSAID use: ~10% of asthmatics have aspirin/NSAID-exacerbated respiratory disease (AERD/Samter's triad: asthma + nasal polyps + NSAID sensitivity). Avoid NSAIDs.
  • Cough-variant asthma: Chronic cough only, no wheeze. Spirometry may be normal → methacholine challenge.
★ Memory Trick
SABA-only = NEVER in 2024. "Every asthmatic gets ICS, even mild ones." LABA in asthma: "LABA alone = death risk → always marry it to ICS" Silent chest: "Quiet = Danger. Wheezing = still moving air. Silence = moving NOTHING." PaCO₂ rising in asthma: "Normal CO₂ is ABNORMAL — they should be blowing it off" Mg in severe asthma: "Mag relaxes bronchospasm when nothing else works — 2g IV over 20 min"
Clinical Vignette
A 22-year-old woman with asthma presents with severe dyspnea. On exam: she can only speak 2–3 words at a time, HR 128, RR 34, SpO₂ 88%. Lung exam shows minimal wheezing. ABG: pH 7.38, PaCO₂ 42, PaO₂ 55.
Answer: This is a life-threatening asthma exacerbation. The PaCO₂ of 42 is ABNORMAL — she should be hyperventilating with PaCO₂ in the 30s. "Minimal wheezing" with severe clinical distress = near-silent chest from severe obstruction. Start continuous albuterol + ipratropium nebulization, IV methylprednisolone, IV magnesium 2g, and prepare for intubation. ICU admission.
Rapid Review Bullets
  • Asthma = reversible obstruction (≥12% + ≥200mL FEV1 improvement post-BD)
  • GINA preferred reliever: ICS-formoterol (budesonide-formoterol) — even for PRN use
  • IV Mg 2g: for severe exacerbation not responding to bronchodilators
  • O₂ target in asthma exacerbation: SpO₂ 93–95% (not 100%)
  • Biologics for step 5: dupilumab, mepolizumab, benralizumab, omalizumab (if allergic)
  • Steroid course for exacerbation: 5 days, no taper needed if ≤7 days
Before you beginCOPD3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · Medium · COPD · Spirometric Diagnosis
A 64-year-old man with 45 pack-years reports chronic productive cough and exertional dyspnea. Spirometry shows FEV₁ 58% predicted with FEV₁/FVC 0.62 pre-bronchodilator; post-bronchodilator FEV₁/FVC is 0.64 with a 6% (120 mL) improvement in FEV₁. Which statement best establishes the diagnosis?
Click to Reveal Answer
Correct answer: A — A post-bronchodilator FEV₁/FVC below 0.70 establishes persistent airflow limitation
GOLD requires a post-bronchodilator FEV₁/FVC below 0.70 to establish the persistent airflow limitation that defines COPD. This patient’s post-bronchodilator ratio of 0.64 satisfies it. Diagnosis and severity are two separate steps: the ratio diagnoses, and the FEV₁ percent predicted then grades severity as GOLD 1 through 4.
Why the other choices are wrong
  • The FEV₁ of 58% predicted establishes the diagnosis independent of the ratio — Incorrect. FEV₁ percent predicted grades severity only. A reduced FEV₁ with a preserved ratio suggests a restrictive process, not COPD — which is exactly why the ratio, not the FEV₁, carries the diagnosis.
  • The absence of significant reversibility excludes asthma and thereby establishes COPD — Incorrect. Reversibility is supportive but not decisive in either direction. Longstanding asthma with airway remodeling can develop fixed obstruction, COPD can show partial reversibility, and asthma-COPD overlap exists. Diagnosis rests on the post-bronchodilator ratio plus exposure history and symptoms.
  • Chest CT demonstrating emphysematous change is required for diagnosis — Incorrect. CT characterizes emphysema distribution, evaluates candidacy for lung volume reduction, and screens for malignancy — but it is never required to diagnose COPD, and a normal CT does not exclude it.
  • A DLCO below 80% predicted is required to confirm the diagnosis — Incorrect. DLCO helps distinguish phenotypes — reduced in emphysema, preserved in chronic bronchitis — but it is not a diagnostic criterion.
Board pearlHold the two-step sequence separately in mind: the post-bronchodilator ratio <0.70 diagnoses; the FEV₁ percent predicted grades. Be aware that the fixed 0.70 cutoff overdiagnoses in the elderly, whose ratio falls naturally with age, and underdiagnoses in the young — which is why some argue for the lower limit of normal instead. The fixed cutoff is what boards test.
Covered below under Module 2 — COPD
Question 2 of 3 · High Yield · COPD · GOLD Group B Initial Therapy
A 68-year-old woman with spirometrically confirmed COPD has an mMRC score of 3 and a CAT score of 18, with no exacerbations in the past year. She currently uses albuterol as needed only. According to current GOLD recommendations, what initial maintenance therapy is preferred?
Click to Reveal Answer
Correct answer: E — LABA plus LAMA dual bronchodilator therapy
A high symptom burden (mMRC ≥2 or CAT ≥10) with 0–1 exacerbations not requiring hospitalization defines GOLD Group B. Current GOLD recommends LABA + LAMA dual bronchodilation as initial therapy for Group B, based on superior lung function, symptom relief, and exacerbation reduction compared with either agent alone, at comparable tolerability.
Why the other choices are wrong
  • Inhaled corticosteroid monotherapy — Incorrect. ICS monotherapy is not recommended in COPD at any stage. It offers no mortality benefit, and it carries pneumonia, candidiasis, and dysphonia risk. ICS in COPD is always part of a combination.
  • Continue as-needed short-acting bronchodilator alone — Incorrect. As-needed short-acting therapy alone corresponds to Group A — minimal symptoms, low exacerbation risk. This patient is highly symptomatic and needs maintenance bronchodilation.
  • LABA plus inhaled corticosteroid combination — Incorrect. LABA + ICS is not a preferred COPD regimen. When ICS is indicated — Group E with blood eosinophils ≥300 cells/µL, or concomitant asthma — triple LABA + LAMA + ICS is superior to LABA + ICS.
  • Oral theophylline with as-needed albuterol — Incorrect. Theophylline is a third-line agent with a narrow therapeutic index and abundant drug interactions, and it has no role in initial maintenance therapy.
Board pearlThe GOLD groups are A, B, and E — the old four-group A/B/C/D scheme is retired, so any chart still showing four boxes needs replacing. Initial therapy: A = a bronchodilator; B = LABA + LAMA; E = LABA + LAMA, adding ICS when eosinophils are ≥300 cells/µL. Group B moving from monotherapy to dual bronchodilation is the change most likely to catch someone who studied from an older source.
Covered below under Module 2 — COPD
Question 3 of 3 · High Yield · COPD · Oxygen Titration and Hypercapnia
A 72-year-old man with severe COPD presents with an exacerbation and is placed on high-flow oxygen, raising his SpO₂ to 99%. Two hours later he is somnolent. ABG: pH 7.24, PaCO₂ 78 mmHg (baseline 52), HCO₃⁻ 32 mEq/L. What is the best next step?
Click to Reveal Answer
Correct answer: C — Reduce supplemental oxygen to target SpO₂ 88–92% and initiate noninvasive positive pressure ventilation
Oxygen in COPD is titrated to a target of SpO₂ 88–92%, not maximized. Excess oxygen worsens hypercapnia through loss of hypoxic pulmonary vasoconstriction with increased dead-space ventilation, the Haldane effect, and some reduction in minute ventilation. Acute hypercapnic respiratory failure with pH below 7.35 is the trigger for NIV, which reduces both intubation rates and mortality in COPD exacerbation.
Why the other choices are wrong
  • Intubate immediately for invasive mechanical ventilation — Incorrect as the next step. Intubation is appropriate if NIV fails or is contraindicated — inability to protect the airway, hemodynamic instability, copious secretions, facial trauma. This patient warrants a monitored NIV trial first, with intubation prepared.
  • Discontinue oxygen entirely until the PaCO₂ falls — Incorrect, and the mirror-image error of the one that created this situation. Hypoxia kills faster than hypercapnia. Never strip oxygen from a hypoxic patient — titrate it down to target.
  • Administer IV sodium bicarbonate to correct the acidemia — Incorrect. The acidosis here is respiratory, caused by inadequate ventilation. Bicarbonate does not improve ventilation and generates additional CO₂ that a failing patient cannot clear.
  • Give IV methylprednisolone and continue the current oxygen delivery — Incorrect. Systemic corticosteroids are indeed indicated in this exacerbation, but continuing the excess oxygen leaves the precipitant in place and ignores the ventilatory failure that now dominates.
Board pearlTwo oxygen numbers, two different situations. Acute exacerbation: titrate to SpO₂ 88–92%. Long-term oxygen therapy: indicated for resting PaO₂ ≤55 mmHg or SpO₂ ≤88%, or PaO₂ 56–59 mmHg with cor pulmonale or polycythemia — and it must be used ≥15 hours daily to deliver the survival benefit shown in the NOTT trial. Nocturnal-only oxygen does not.
Covered below under Module 2 — COPD
Tier 1
Domain 1 · Highest PANCE Weight
Module 2
Chronic Obstructive Pulmonary Disease (COPD)
👁 Free Preview
GOLD 2026 ABE Groups · Pharmacotherapy · LTOT · BiPAP · Exacerbation
★★★ PANCE PriorityGOLD 2026 Updated
Core Recognition & Diagnosis
  • Post-bronchodilator FEV1/FVC <0.70 confirms fixed airflow obstruction
  • Emphysema: Destruction of alveolar walls → air trapping, barrel chest, decreased breath sounds, pursed-lip breathing, hyperinflation on CXR
  • Chronic bronchitis: Productive cough ≥3 months/year for ≥2 consecutive years. "Blue bloaters" — hypercapnia, cor pulmonale
  • COPD vs Asthma: COPD = irreversible (or minimally reversible). Asthma = reversible. Key distinction on PANCE.
GOLD 2026 Classification
SPIROMETRIC SEVERITY (GOLD 1-4)
GradeFEV1 % Predicted
GOLD 1 (Mild)≥80%
GOLD 2 (Moderate)50–79%
GOLD 3 (Severe)30–49%
GOLD 4 (Very Severe)<30%
ABE GROUPS (2023 UPDATE)
GroupSymptomsExacerbations
ALow (mMRC <2, CAT <10)0–1/year, no hospitalization
BHigh (mMRC ≥2, CAT ≥10)0–1/year, no hospitalization
EAny≥2/year OR ≥1 hospitalization

Groups C and D were merged into Group E in the 2023 GOLD update.

Pharmacotherapy by GOLD Group
GroupInitial TreatmentEscalationICS?
ASingle bronchodilator (LAMA or LABA)Add second bronchodilatorNo
BLAMA + LABA (dual bronchodilator)Triple therapy if still symptomaticNo (unless eos ≥300)
ELAMA + LABATriple therapy (ICS/LABA/LAMA) if blood eos ≥300 or continued exacerbationsConsider if eos ≥300
  • Blood eosinophil count guides ICS use in COPD: ≥300 cells/μL = likely benefit from ICS; <100 = unlikely benefit; 100–300 = depends on exacerbation frequency
  • LABA monotherapy is ACCEPTABLE in COPD (unlike asthma where it is contraindicated alone)
  • ICS monotherapy is NEVER appropriate in COPD — always combine with long-acting bronchodilator
  • Roflumilast (PDE4 inhibitor): For severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy
Non-Pharmacologic Management
  • Smoking cessation: Single most important intervention to slow FEV1 decline. Offer varenicline (first-line), bupropion, or nicotine replacement.
  • Pulmonary rehabilitation: Improves exercise capacity, dyspnea, and QOL. Recommended for GOLD B and E.
  • Long-Term Oxygen Therapy (LTOT):
LTOT Indications (Use ≥15 hours/day)
  • PaO₂ ≤55 mmHg OR SpO₂ ≤88% at rest — primary indication
  • PaO₂ 55–60 mmHg WITH evidence of: pulmonary hypertension, cor pulmonale, or polycythemia (Hct >55%)
  • LTOT does NOT benefit moderate hypoxemia (SpO₂ 89–93%) — LOTT trial: no survival or hospitalization benefit
  • LTOT does NOT benefit exercise-induced desaturation only
  • O₂ target in COPD: 88–92% — excessive O₂ worsens hypercapnia in CO₂ retainers (suppresses hypoxic drive)
  • Vaccinations: Influenza (annual), pneumococcal (PCV20), COVID-19, RSV (age ≥60)
COPD Exacerbation Management
  • Bronchodilators: Increase SABA ± ipratropium frequency
  • Systemic corticosteroids: Prednisone 40 mg PO × 5 days (no taper) — longer courses show no benefit
  • Antibiotics: Indicated when ≥2 of: increased dyspnea, increased sputum volume, increased sputum purulence (Anthonisen criteria) — amoxicillin/clavulanate, azithromycin, or doxycycline
  • NIV (BiPAP): First-line for acute hypercapnic respiratory failure (pH <7.35, PaCO₂ >45) — reduces intubation rate, mortality, and ICU length of stay
⚑ Board Traps — COPD
  • ICS monotherapy is NEVER appropriate in COPD — always combine with LABA or LAMA
  • ICS in COPD increases pneumonia risk — use only when clearly indicated
  • LTOT target SpO₂ is 88–92% — do NOT target 95–100% in CO₂ retainers
  • LTOT does NOT help moderate hypoxemia (SpO₂ 89–93%) — LOTT trial proved no benefit
  • BiPAP is first-line for COPD exacerbation with respiratory failure — NOT intubation. Intubate only if BiPAP fails or is contraindicated.
  • COPD exacerbation antibiotics: Indicated for purulent sputum — unlike asthma where antibiotics are NOT routine
  • GOLD Groups C and D no longer exist — merged into Group E in 2023 update
  • Alpha-1 antitrypsin deficiency: Think COPD in a never-smoker <45 with lower lobe-predominant emphysema
★ Memory Trick
COPD O₂ target: "88–92% — not too much, not too little" LTOT: "55 or less = definitely yes. 89–93% only = LOTT trial says NO." BiPAP in COPD: "B for BEFORE intubation — always try BiPAP first" COPD ABE: "A = Any bronchodilator. B = Both LAMA+LABA. E = Exacerbations = consider triple + ICS if eos ≥300" "LABA alone OK in COPD — NOT in asthma" (asthma = LABA needs ICS partner always)
Before you beginPneumonia3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · High Yield · Pneumonia · Atypical Organism Recognition
A 56-year-old man has five days of fever, dry cough, confusion, and watery diarrhea. Sodium is 128 mEq/L and transaminases are mildly elevated. Chest radiograph shows a patchy left lower lobe infiltrate. He recently returned from a hotel stay where he used the hot tub daily. Which test best identifies the causative organism?
Click to Reveal Answer
Correct answer: A — Urine antigen testing
The constellation of hyponatremia, diarrhea, confusion, transaminitis, and water-source exposure is classic Legionella pneumophila. Urine antigen is the rapid first-line test, detecting serogroup 1, which accounts for roughly 80–90% of clinical cases. Treat with a respiratory fluoroquinolone such as levofloxacin, or azithromycin.
Why the other choices are wrong
  • Cold agglutinin titer — Incorrect. Cold agglutinins point to Mycoplasma pneumoniae — the younger patient with protracted dry cough, sometimes with bullous myringitis or a rash. Mycoplasma does not produce this hyponatremia-diarrhea-transaminitis triad.
  • Sputum acid-fast bacilli smear — Incorrect. AFB smear evaluates tuberculosis, which follows a subacute-to-chronic course with weight loss and night sweats, typically producing upper-lobe or cavitary disease rather than this five-day illness.
  • Serum procalcitonin — Incorrect. Procalcitonin can support a bacterial rather than viral etiology and helps guide antibiotic duration, but it identifies no organism and would not change the empiric choice here.
  • Nasopharyngeal viral PCR panel — Incorrect. Reasonable to send in many pneumonia workups, but a viral pathogen would not account for the hyponatremia, transaminitis, and hot tub exposure that define this presentation.
Board pearlLearn the atypicals by their fingerprint rather than as a list. Legionella — hyponatremia, diarrhea, confusion, transaminitis, water exposure; urine antigen; invisible on Gram stain and requires buffered charcoal yeast extract agar to culture. Mycoplasma — young patient, dry hacking cough, cold agglutinins, bullous myringitis. Chlamydophila — hoarseness, gradual onset. Coxiella (Q fever) — livestock and parturient animal exposure.
Covered below under Module 3 — Pneumonia
Question 2 of 3 · High Yield · Pneumonia · CURB-65 and Empiric Therapy
A 74-year-old man with COPD and chronic kidney disease presents with pneumonia. He is confused. Respiratory rate 26, BP 88/54 mmHg, BUN 32 mg/dL. What is his CURB-65 score, and what disposition and empiric therapy follow?
Click to Reveal Answer
Correct answer: D — Score 4 — ICU admission; IV beta-lactam plus a macrolide
CURB-65 awards one point each for Confusion, Urea (BUN >19 mg/dL), Respiratory rate ≥30, Blood pressure (SBP <90 or DBP ≤60), and age ≥65. This patient scores for confusion, BUN 32, SBP 88, and age 74 — 4 points. A score of 4–5 carries mortality above 25% and warrants ICU-level care. Empiric therapy for severe CAP is a beta-lactam (ceftriaxone, cefotaxime, or ampicillin-sulbactam) plus either a macrolide or a respiratory fluoroquinolone.
Why the other choices are wrong
  • Score 2 — outpatient doxycycline with 48-hour follow-up — Incorrect. This substantially undercounts. Outpatient management applies to scores of 0–1, and oral monotherapy in a hypotensive, confused patient would be unsafe regardless of the score.
  • Score 3 — floor admission; oral amoxicillin-clavulanate plus doxycycline — Incorrect. The score is 4, and oral therapy is inappropriate with a systolic pressure of 88 and altered mentation.
  • Score 5 — ICU admission; vancomycin plus piperacillin-tazobactam — Incorrect on both halves. Respiratory rate 26 does not score — the threshold is ≥30 — so the total is 4, not 5. And vancomycin plus piperacillin-tazobactam is HAP/VAP coverage, or CAP with documented MRSA and Pseudomonas risk factors, not routine severe CAP.
  • Score 4 — floor admission; azithromycin monotherapy — Incorrect. The score is right, but macrolide monotherapy is inadequate for severe CAP given pneumococcal macrolide resistance, and a score of 4 calls for ICU-level monitoring rather than the floor.
Board pearlThe thresholds are where this question is won or lost, and respiratory rate is the one most often misremembered: RR ≥30, not ≥20. BUN >19 mg/dL (7 mmol/L). SBP <90 or DBP ≤60. Disposition: 0–1 outpatient, 2 inpatient, 3–5 severe with ICU assessment at 4–5. Remember what the tool is for — CURB-65 predicts mortality; formal ICU triage uses the IDSA/ATS major and minor severity criteria.
Covered below under Module 3 — Pneumonia
Question 3 of 3 · High Yield · Pneumonia · CAP vs HAP Trap
A 61-year-old man was admitted for elective hip arthroplasty. On hospital day 6, having never been intubated, he develops fever, purulent sputum, and a new right lower lobe infiltrate. What is the most appropriate empiric regimen?
Click to Reveal Answer
Correct answer: B — Piperacillin-tazobactam
Pneumonia beginning ≥48 hours after admission is hospital-acquired pneumonia, regardless of whether the patient was ever intubated — the point students most often miss, because HAP gets mentally filed with ventilators. HAP requires empiric antipseudomonal coverage: piperacillin-tazobactam, cefepime, meropenem, or levofloxacin at antipseudomonal dosing. Add MRSA coverage for prior IV antibiotics within 90 days, or unit MRSA prevalence above 20% or unknown.
Why the other choices are wrong
  • Ceftriaxone plus azithromycin — Incorrect, and this is the trap. It is a textbook CAP regimen with no antipseudomonal activity, chosen because the presentation looks like ordinary pneumonia. Six days of hospitalization changes the expected flora entirely.
  • Vancomycin monotherapy — Incorrect. Vancomycin covers MRSA and provides no gram-negative activity whatsoever, leaving the most likely pathogens in this setting untreated.
  • Amoxicillin-clavulanate plus doxycycline — Incorrect. This is oral outpatient CAP therapy — wrong spectrum and wrong route for a hospitalized patient with hospital-acquired infection.
  • Moxifloxacin monotherapy — Incorrect, and a useful pharmacologic distinction. Among the fluoroquinolones, moxifloxacin lacks reliable antipseudomonal activity, unlike levofloxacin and ciprofloxacin. It is a respiratory fluoroquinolone for CAP, not an agent for HAP.
Board pearlThe clock, not the ventilator, defines HAP: onset ≥48 hours after admission. Cover Pseudomonas empirically. Add MRSA coverage for IV antibiotics within 90 days or high/unknown local prevalence, and use two antipseudomonal agents when mortality risk is high or structural lung disease such as bronchiectasis is present. Carry one pharmacology fact alongside it — moxifloxacin is not antipseudomonal.
Covered below under Module 3 — Pneumonia
Tier 1
Domain 2 · High PANCE Weight
Module 3
Community-Acquired Pneumonia (CAP)
👁 Free Preview
CURB-65 · PSI · Antibiotic Selection · 3-Day Course Update · Aspiration
Core Recognition & Severity Scoring
  • Classic presentation: Fever, productive cough (purulent or rust-colored), pleuritic chest pain, dyspnea, elevated WBC
  • CXR: Lobar or segmental consolidation. CT is more sensitive if CXR equivocal.
ScoreParametersScore → ActionBoard Key
CURB-65Confusion, Urea (BUN >19), RR ≥30, BP (SBP <90 or DBP ≤60), Age ≥650–1 → Outpatient; 2 → Consider hospitalization; 3–5 → Hospitalize (4–5 → ICU consideration)Simple, 5-point score
PSI (Pneumonia Severity Index)20 variables: age, comorbidities, vitals, labs, CXRClass I–III → Outpatient; Class IV → Consider hospitalization; Class V → HospitalizePreferred by ATS/IDSA — identifies more low-risk outpatients. PSI > CURB-65 per guidelines.
Empiric Antibiotic Therapy
SettingFirst-Line TreatmentAlternativeBoard Key
Outpatient — No ComorbiditiesAmoxicillin 1g TID OR doxycycline 100mg BIDAzithromycin ONLY if local pneumococcal resistance <25%Azithromycin monotherapy NOT recommended in most US regions (resistance >30%)
Outpatient — With ComorbiditiesAmoxicillin/clavulanate or cephalosporin (cefpodoxime, cefuroxime) + macrolide or doxycyclineRespiratory fluoroquinolone monotherapy (levofloxacin 750mg or moxifloxacin 400mg)Fluoroquinolones: only if β-lactam/macrolide cannot be used
Inpatient — Non-Severeβ-lactam (ceftriaxone) + macrolide (azithromycin)Respiratory fluoroquinolone monotherapyCombination preferred
Inpatient — Severe/ICUβ-lactam (ceftriaxone or ampicillin/sulbactam) + macrolide or fluoroquinolone+ anti-MRSA (vancomycin/linezolid) + anti-pseudomonal ONLY if specific risk factorsIV hydrocortisone 200mg/day reduces mortality in severe CAP (CAPE COD trial)

Duration: Minimum 3–5 days guided by clinical stability criteria (afebrile, HR <100, RR <24, SBP ≥90, SpO₂ ≥90%, able to eat, normal mentation). Longer courses NOT superior.

⚑ Board Traps — CAP
  • Fluoroquinolones are NOT first-line for CAP — reserve for β-lactam/macrolide intolerance (C. diff risk, tendon rupture, QT prolongation, resistance selection)
  • Azithromycin monotherapy is NOT recommended as empiric outpatient CAP — macrolide resistance in S. pneumoniae exceeds 30% in most US regions
  • Do NOT add anti-anaerobic coverage (metronidazole, clindamycin) for aspiration pneumonia — associated with 5–6% higher mortality per 2019 ATS/IDSA guidelines
  • 3-day antibiotic course is sufficient if stability criteria met by day 3 — this is a major update from traditional 7–10 day courses
  • IV steroids (hydrocortisone 200mg/day) reduce mortality in SEVERE CAP — NOT indicated in mild/moderate CAP
  • Legionella: Think in severe CAP + hyponatremia + diarrhea + hepatic involvement + exposure to water systems. Urinary antigen is the diagnostic test. Treat with fluoroquinolone or azithromycin.
★ Memory Trick
CURB-65: "Confusion + Urea + Resp rate + Blood pressure + 65 years" — 1 point each PSI > CURB-65 per ATS/IDSA — "PSI is more precise for low-risk outpatient identification" Aspiration pneumonia: "No anaerobes needed — stop adding metronidazole, it hurts more than helps" CAP course: "3 days if stable by day 3 — not 10. Stability = afebrile, HR/RR normal, eating, O₂ ok" "FQs are the backup plan, not the opening play" — use β-lactam + macrolide first
Clinical Vignette
A 68-year-old woman with diabetes presents with 3 days of fever, productive cough, and RUQ pain. BP 110/70, HR 108, RR 26, SpO₂ 92%. CXR shows right lower lobe consolidation. BUN 22, Na 128. She takes amoxicillin regularly for UTIs.
Answer: CURB-65 = 3 (BUN >19, RR ≥30 approximately, age ≥65) → hospitalize. The hyponatremia + RUQ pain suggest Legionella — order urine Legionella antigen. Antibiotic: β-lactam (ceftriaxone) + macrolide (azithromycin) covers both typical and atypical (including Legionella). If she deteriorates → ICU + consider steroids. Minimum course = 3–5 days if clinical stability met.
Before you beginPulmonary Embolism3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · Medium · PE · Diagnostic Sequencing
A 47-year-old woman presents with acute dyspnea and pleuritic chest pain six days after knee arthroscopy. HR 104, BP 122/78, SpO₂ 93% on room air. Her calves are nontender. What is the most appropriate first step?
Click to Reveal Answer
Correct answer: E — Calculate a validated clinical pretest probability score
The diagnostic algorithm for PE begins with pretest probability — the Wells score or the revised Geneva score. That determination governs everything downstream: at low or intermediate probability a negative D-dimer excludes PE, while at high probability imaging is required regardless of the D-dimer result. Wells assigns 3 points each for clinical signs of DVT and for PE being the most likely diagnosis; 1.5 each for HR >100, immobilization or surgery within four weeks, and prior PE or DVT; and 1 each for hemoptysis and active malignancy.
Why the other choices are wrong
  • Obtain a D-dimer — Incorrect as a first step. D-dimer is uninterpretable without a pretest probability to anchor it, and it is nonspecific — elevated by recent surgery, pregnancy, malignancy, infection, and advancing age. Ordering it first invites a result you cannot act on.
  • Order CT pulmonary angiography — Incorrect here. Going straight to CTPA is correct at high pretest probability, but ordering it before risk stratification skips the step that determines whether imaging is needed at all, and commits the patient to contrast and radiation.
  • Begin therapeutic low-molecular-weight heparin and observe — Incorrect as a diagnostic step. Empiric anticoagulation while awaiting imaging is reasonable when pretest probability is high and bleeding risk is low, but it neither confirms nor excludes the diagnosis.
  • Obtain bilateral lower extremity duplex ultrasonography — Incorrect. A positive duplex in a symptomatic patient supports treating for venous thromboembolism, but a negative study does not exclude PE, since the responsible clot has frequently already embolised.
Board pearlNever let a D-dimer be the first thought. Pretest probability first, and it dictates the pathway. Two refinements worth knowing: the age-adjusted D-dimer threshold (age × 10 ng/mL for patients over 50) reduces unnecessary imaging in older patients, and the PERC rule can spare testing altogether in patients whose probability is already very low.
Covered below under Module 4 — Pulmonary Embolism
Question 2 of 3 · High Yield · PE · First-Line Anticoagulation
CT pulmonary angiography confirms a segmental pulmonary embolism. BP 128/76, HR 92, troponin and BNP are normal, and the right ventricle is normal on echocardiography. There are no bleeding risk factors and creatinine clearance is 80 mL/min. What is the first-line anticoagulation?
Click to Reveal Answer
Correct answer: C — Apixaban or rivaroxaban as monotherapy
For hemodynamically stable low-risk PE, direct oral anticoagulants are first-line. Apixaban and rivaroxaban require no parenteral lead-in — each begins with an intensified loading period — and they match warfarin for efficacy with less major bleeding and no routine monitoring. Treat for a minimum of three months, then reassess the risk-benefit balance for extended therapy.
Why the other choices are wrong
  • IV unfractionated heparin bridged to warfarin with a target INR of 2–3 — Incorrect as first-line, though a wholly acceptable alternative. Warfarin remains preferred in specific settings — antiphospholipid syndrome and severe renal impairment — but for the average stable patient the DOAC has displaced it.
  • Systemic alteplase followed by oral anticoagulation — Incorrect. Thrombolysis is reserved for hemodynamic instability: systolic BP below 90 mmHg for at least 15 minutes, a vasopressor requirement, or cardiac arrest. This patient has a normal RV and normal biomarkers, placing him at low risk, where thrombolysis offers only bleeding.
  • Retrievable IVC filter placement plus aspirin — Incorrect. Filters are for patients with an absolute contraindication to anticoagulation. Here a filter adds procedural risk without treating the existing clot, and aspirin is not adequate therapy for established PE.
  • Dabigatran started immediately without parenteral therapy — Incorrect, and a genuine pharmacologic distinction. Dabigatran and edoxaban require 5–10 days of parenteral heparin first; only apixaban and rivaroxaban can be started as monotherapy from the outset.
Board pearlSort the DOACs by whether they need a heparin lead-in: apixaban and rivaroxaban — no lead-in (loading dose instead); dabigatran and edoxaban — 5–10 days of parenteral heparin first. Then the exceptions: pregnancy takes LMWH, as DOACs are contraindicated; antiphospholipid syndrome takes warfarin; and in cancer-associated thrombosis either a DOAC or LMWH is acceptable, with caution around luminal GI and GU tumors because of bleeding.
Covered below under Module 4 — Pulmonary Embolism
Question 3 of 3 · High Yield · PE · The Negative D-Dimer Trap
A 58-year-old woman with metastatic breast cancer has two days of pleuritic chest pain and dyspnea. HR 112, with unilateral leg swelling and calf tenderness. Her Wells score is 8.5, placing her at high clinical probability. D-dimer returns at 380 ng/mL (reference <500). What is the best next step?
Click to Reveal Answer
Correct answer: D — Proceed with CT pulmonary angiography
D-dimer excludes PE only at low or intermediate pretest probability. When pretest probability is high, the pre-test likelihood of disease is great enough that even a negative result leaves an unacceptable false-negative rate, so imaging is mandatory. Guidelines advise not obtaining a D-dimer at all in high-probability patients, precisely because it cannot change management and a negative result invites the error this question tests.
Why the other choices are wrong
  • PE is excluded by the negative D-dimer; evaluate alternative causes — Incorrect, and the trap. This applies a rule-out test outside the population in which it was validated. Negative predictive value is a function of pretest probability, not a fixed property of the assay — the same negative result means different things in different patients.
  • Repeat the D-dimer in 24 hours — Incorrect. Serial D-dimer testing has no role in PE diagnosis. Repeating an uninformative test does not make it informative.
  • Obtain a ventilation-perfusion scan only if the chest radiograph is abnormal — Incorrect. V/Q scanning is the alternative when CTPA is contraindicated — severe renal impairment, contrast allergy, pregnancy — and the choice does not hinge on radiograph findings. In fact V/Q performs best when the chest film is normal.
  • Discharge on prophylactic-dose anticoagulation with outpatient follow-up — Incorrect. Prophylactic dosing never treats suspected or confirmed PE, and discharging a high-probability patient without imaging abandons the workup at its most dangerous point.
Board pearlGeneralise the principle rather than memorising the case: a rule-out test only rules out when pretest probability is low enough. D-dimer’s entire value lives at low and intermediate probability. At high probability, skip it and image — ordering it can only mislead. The same reasoning governs every high-sensitivity screening test you will be asked about.
Covered below under Module 4 — Pulmonary Embolism
Tier 1
Domain 4 · High Yield
Module 4
Pulmonary Embolism
👁 Free Preview
Wells · PERC · CTPA · Massive vs Submassive · DOACs · 2026 AHA/ACC Guidelines
Core Recognition & Diagnostic Algorithm
  • Classic triad: Dyspnea + pleuritic chest pain + hemoptysis (present in <20% of cases — classic but rare)
  • Most common symptom: Dyspnea alone
  • EKG findings: Sinus tachycardia (#1), S1Q3T3 (classic but insensitive), new RBBB, T-wave inversions V1–V4
  • Massive PE: Sudden hemodynamic collapse, RV strain on echo, troponin and BNP elevation
Stepwise Diagnostic Approach
Wells Score + PERC + D-Dimer Algorithm
  • Step 1: Calculate Wells score. Score ≤4 = PE unlikely → proceed to PERC or D-dimer. Score >4 = PE likely → CTPA directly.
  • PERC rule: If low pretest probability (<15%) AND all 8 criteria met → PE excluded without D-dimer (age <50, HR <100, SpO₂ >94%, no prior VTE, no surgery/trauma, no hemoptysis, no unilateral leg swelling, no estrogen use)
  • D-dimer: For low/intermediate probability. If negative (<500 ng/mL or age-adjusted: age × 10 for age >50) → PE excluded. If positive → CTPA.
  • CTPA: Gold standard imaging — sensitivity ~98%, specificity ~97%.
  • V/Q scan: Alternative if CTPA contraindicated (contrast allergy, renal insufficiency, pregnancy)
Risk Stratification & Treatment
CategoryDefinitionMortalityTreatment
Massive PE (High-risk)SBP <90 mmHg or vasopressor requirement or cardiac arrest~5–58%Systemic thrombolysis (alteplase 100mg IV over 2h) + anticoagulation. Surgical embolectomy or catheter-directed therapy if lytics contraindicated.
Submassive (Intermediate)Hemodynamically stable + RV dysfunction on echo/CT AND/OR elevated troponin or BNP~3–15%Anticoagulation alone. Consider catheter-directed thrombolysis (CDT) or systemic lytics ONLY if hemodynamic deterioration occurs.
Low-risk PEHemodynamically stable, no RV dysfunction, normal biomarkers (PESI Class I–II)<1%DOACs. Consider outpatient treatment if PESI low-risk, no contraindications, and reliable follow-up.
Anticoagulation Selection
AgentParenteral Bridge?Key Notes
Apixaban (preferred)NO10mg BID × 7d, then 5mg BID. Most commonly used DOAC for PE.
RivaroxabanNO15mg BID × 21d, then 20mg daily.
DabigatranYES — 5–10 days LMWH firstThen dabigatran PO. Cannot use without parenteral lead-in.
EdoxabanYES — 5–10 days LMWH firstThen edoxaban PO.
WarfarinYES — heparin bridge until INR ≥2Second-line. First-line for: antiphospholipid syndrome, mechanical valves.
LMWH—Preferred for cancer-associated VTE (though DOACs now acceptable for most cancer patients without GI/GU malignancy)
Duration of Anticoagulation
  • Provoked PE (reversible major risk factor — surgery, trauma, immobility): 3 months, then stop
  • Unprovoked PE: Extended (indefinite) anticoagulation — reduced-dose apixaban 2.5mg BID or rivaroxaban 10mg daily after initial 6 months
  • Cancer-associated PE: Continue as long as cancer active
  • First unprovoked + high bleeding risk: 3–6 months then reassess — shared decision-making
⚑ Board Traps — PE
  • DOACs are first-line for PE treatment — warfarin is no longer preferred (except antiphospholipid syndrome)
  • DOACs are absolutely contraindicated in antiphospholipid syndrome — use warfarin (TRAPS trial: DOACs inferior)
  • Thrombolysis for MASSIVE PE only (SBP <90) — NOT for submassive PE unless hemodynamic deterioration
  • IVC filter: ONLY if anticoagulation absolutely contraindicated — NOT as routine adjunct to anticoagulation
  • D-dimer is a RULE-OUT test ONLY — do NOT order in high-probability patients (go straight to CTPA). Positive D-dimer does NOT diagnose PE.
  • PERC only applies to LOW pre-test probability (<15%) — never apply to moderate or high-risk patients
  • Subsegmental PE in low-risk patients without DVT: May observe without anticoagulation — evolving evidence
  • Apixaban and rivaroxaban require NO initial parenteral anticoagulation — dabigatran and edoxaban DO require 5–10 days of LMWH first
★ Memory Trick
Wells ≤4 + PERC negative = NO PE (no imaging needed) Wells ≤4 + PERC positive = D-dimer Wells >4 = CTPA directly (skip D-dimer) DOACs: "Apixaban and Rivaroxaban = No bridge needed. Dabigatran and Edoxaban = Need 5-10 days LMWH first." Thrombolysis: "Massive PE (SBP <90) = lyse. Submassive = wait. Low-risk = DOAC and go home." APS: "Antiphospholipid syndrome = Warfarin ONLY. DOACs fail in APS."
Clinical Vignette
A 35-year-old woman on oral contraceptives presents with 3 days of right pleuritic chest pain and dyspnea. HR 105, SpO₂ 94%, RR 20. Wells score = 5 (HR >100 + PE most likely dx). Echo shows RV dilation. Troponin is elevated. CTPA confirms bilateral PE. BP is 118/76.
Answer: Submassive (intermediate-risk) PE — hemodynamically stable but RV dysfunction + elevated troponin. Start anticoagulation immediately (apixaban 10mg BID × 7 days — no bridge needed). Do NOT give systemic thrombolytics unless BP drops below 90. Admit for monitoring. If she deteriorates hemodynamically → consider catheter-directed therapy or systemic lytics. Anticoagulate for at least 3 months (OCP is a provoked risk factor — stop OCP); consider extended therapy given her age and continued OCP risk if it would be resumed.
Before you beginPleural Effusions3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · Medium · Pleural Effusion · Light's Criteria
A 63-year-old man has a new unilateral pleural effusion. Thoracentesis shows pleural protein 3.9 g/dL (serum 6.5), pleural LDH 260 IU/L (serum 180, upper limit of normal 230). How should this effusion be classified, and what follows?
Click to Reveal Answer
Correct answer: C — Exudate — pursue evaluation for infection, malignancy, or inflammation
Light’s criteria classify an effusion as exudative if any one of the following is met: pleural/serum protein ratio >0.5; pleural/serum LDH ratio >0.6; pleural LDH greater than two-thirds the upper limit of normal serum LDH. Here the protein ratio is 0.60, the LDH ratio is 1.44, and pleural LDH of 260 exceeds 153 — all three are satisfied. An exudate demands an etiologic search: infection, malignancy, PE, autoimmune disease, or chylothorax.
Why the other choices are wrong
  • Transudate — consistent with heart failure or cirrhosis — Incorrect. A transudate fails all three criteria. Transudates arise from altered hydrostatic or oncotic pressure across an intact pleura — heart failure, cirrhosis, nephrotic syndrome — and this fluid meets every criterion for exudate.
  • Transudate — no further diagnostic workup is indicated — Incorrect twice over. The fluid is exudative, and even a confirmed transudate warrants attention to the systemic cause producing it.
  • Exudate — but the classification is valid only when all three of Light's criteria are met — Incorrect, and a common misconception. Any single criterion is sufficient. The criteria are deliberately weighted toward sensitivity, accepting some false-positive exudates as the price of missing very few true ones.
  • Chylothorax — confirmed by the elevated pleural LDH — Incorrect. Chylothorax requires pleural triglycerides above 110 mg/dL or the presence of chylomicrons, usually with milky fluid. LDH says nothing about it.
Board pearlCommit the three criteria and the “any one” rule to memory: protein ratio >0.5, LDH ratio >0.6, pleural LDH >⅔ the serum upper limit. Sensitivity is roughly 98%, and the design is intentional — the criteria over-call exudates rather than risk missing one. Knowing that they are sensitive but not specific is what sets up the correction you will need in the diuresed heart failure patient.
Covered below under Module 5 — Pleural Effusions
Question 2 of 3 · High Yield · Pleural Effusion · Complicated Parapneumonic
A 55-year-old man admitted with community-acquired pneumonia has a moderate effusion that enlarges despite three days of appropriate IV antibiotics. Thoracentesis yields turbid fluid: pH 7.08, glucose 32 mg/dL, LDH 1450 IU/L, with a negative Gram stain. What is the best next step?
Click to Reveal Answer
Correct answer: A — Chest tube drainage in addition to antibiotics
This is a complicated parapneumonic effusion, defined by pH <7.20, glucose <60 mg/dL, LDH >1000 IU/L, a positive Gram stain or culture, or frank pus (empyema). It requires drainage plus antibiotics. Critically, a negative Gram stain does not exclude the diagnosis — the biochemical profile alone establishes it. Left undrained, the space progresses to loculation, empyema, and fibrothorax requiring decortication.
Why the other choices are wrong
  • Continue IV antibiotics alone and repeat imaging in 48 hours — Incorrect, and the trap this question is built on — treating a complicated effusion as a simple reactive one. Antibiotics penetrate infected pleural fluid poorly, and this collection is already enlarging on adequate therapy.
  • Repeat thoracentesis in 48 hours if symptoms persist — Incorrect. Delay permits fibrin deposition and loculation, converting a collection that a chest tube could drain today into a surgical problem next week.
  • Intrapleural tPA and DNase as the sole additional therapy — Incorrect as a substitute. Intrapleural fibrinolytics plus DNase are an adjunct for loculated collections that fail tube drainage, not a replacement for the tube itself.
  • Video-assisted thoracoscopic decortication as the initial intervention — Incorrect as an initial step. VATS is reserved for failed tube drainage with persistent loculation or trapped lung. Starting with surgery skips an effective, far less invasive intervention.
Board pearlMemorise the drainage triggers as a set: pH <7.20, glucose <60, LDH >1000, positive Gram stain or culture, or frank pus. Any one mandates a chest tube. Two practical points that decide the answer — a negative Gram stain does not reassure, and pleural fluid pH must be collected in a blood gas syringe and processed promptly, since air exposure and delay both distort it.
Covered below under Module 5 — Pleural Effusions
Question 3 of 3 · High Yield · Pleural Effusion · The Diuresed Transudate Trap
A 78-year-old woman with HFrEF has bilateral pleural effusions and has received furosemide 80 mg twice daily for five days. Thoracentesis: pleural protein 3.2 g/dL (serum 5.4), pleural LDH 190 IU/L (serum 260), pleural albumin 2.3 g/dL, serum albumin 3.8 g/dL. Light's criteria indicate an exudate. What is the most appropriate interpretation?
Click to Reveal Answer
Correct answer: B — Likely transudate — the serum-to-pleural albumin gradient exceeds 1.2 g/dL
Diuresis concentrates pleural protein and LDH, pushing a cardiac transudate falsely into the exudate range in up to a quarter of diuresed heart failure patients. When the clinical picture says transudate but Light’s says exudate, apply the serum-to-pleural albumin gradient: greater than 1.2 g/dL indicates a transudate. Here 3.8 − 2.3 = 1.5 g/dL. The serum-to-pleural protein gradient above 3.1 g/dL serves the same corrective purpose.
Why the other choices are wrong
  • Exudate — proceed to chest CT and pleural biopsy for malignancy — Incorrect. This commits the patient to invasive workup on the strength of a well-described false positive. Bilateral effusions in decompensated heart failure under active diuresis are transudative until something else proves otherwise.
  • Exudate — begin empiric antibiotics for occult infection — Incorrect. Nothing here suggests infection: no fever is described, and the pH and glucose are nowhere near the complicated parapneumonic range.
  • Indeterminate — Light's criteria cannot be applied to bilateral effusions — Incorrect. Light’s criteria apply regardless of laterality. Bilateral effusions do favor a systemic transudative cause, but that is a reason to check the albumin gradient, not to abandon classification.
  • Exudate — the LDH ratio is the most specific criterion and overrides the clinical picture — Incorrect. Light’s criteria are sensitive rather than specific, and no single criterion overrides clinical context. Reasoning that pushes a laboratory ratio ahead of a coherent clinical story is how this patient ends up with an unnecessary biopsy.
Board pearlThis is the most testable failure mode of a rule you just learned. Diuresed heart failure is the classic Light’s false positive, and the rescue is the serum−pleural albumin gradient >1.2 g/dL (or protein gradient >3.1 g/dL) reclassifying it as transudate. Two more fluid patterns worth carrying: a bloody effusion suggests malignancy, PE with infarction, or trauma, and pleural fluid eosinophilia suggests blood or air in the space, drug reaction, or parasitic infection.
Covered below under Module 5 — Pleural Effusions
Tier 1
Domain 5 · High Yield
Module 5
Pleural Effusions
👁 Free Preview
Light's Criteria · Transudate vs Exudate · Parapneumonic · Empyema · pH <7.2
Light's Criteria — Exudate if ANY ONE Met
Light's Criteria (All 3 Together — Exudate if ANY one positive)
  • Pleural fluid protein / Serum protein >0.5
  • Pleural fluid LDH / Serum LDH >0.6
  • Pleural fluid LDH >2/3 the upper limit of normal serum LDH
  • Sensitivity ~98%, Specificity ~72% — misclassifies ~25% of transudates as exudates (especially diuretic-treated HF)
Common Causes
Transudate (SAAG ≥1.2, or Light's negative)Exudate (Light's positive)
Heart failure (#1 overall cause)Parapneumonic / Empyema (#1 exudative)
Cirrhosis (hepatic hydrothorax)Malignancy (#2 exudative)
Nephrotic syndromePulmonary embolism (can be either)
HypothyroidismTB pleuritis (lymphocytic exudate)
Autoimmune (RA — very low glucose; SLE)
Parapneumonic Effusions — The pH <7.2 Rule
TypeFluid CharacteristicsTreatment
Simple parapneumonicpH >7.2, glucose >60, LDH <1000, cultures negativeAntibiotics alone — will resolve
Complicated parapneumonicpH ≤7.2, glucose ≤60, LDH >1000, OR positive culture/Gram stainAntibiotics + chest tube drainage (MANDATORY)
EmpyemaFrank pus in pleural spaceAntibiotics + chest tube drainage. If loculated → fibrinolytics instilled intrapleurally or VATS decortication.
Additional Diagnostic Tests
  • Pleural fluid pH: Most important single test for complicated parapneumonic — pH ≤7.2 = drain
  • Glucose: Very low (<30) = RA (rheumatoid arthritis) or empyema. RA is the lowest.
  • Triglycerides >110: Chylothorax (thoracic duct injury) — creamy white milky appearance
  • Hematocrit >50% of serum Hct: Hemothorax — requires chest tube
  • Elevated amylase: Pancreatitis, esophageal rupture (Boerhaave)
  • Pleural fluid ADA >40: TB pleuritis (in appropriate geographic/clinical context)
⚑ Board Traps — Pleural Effusions
  • Light's criteria can misclassify HF effusions as exudates in diuretic-treated patients — if HF is the suspected cause but Light's says exudate → check serum-to-pleural albumin gradient (>1.2 g/dL = transudate)
  • NT-proBNP >1500 pg/mL in pleural fluid = HF etiology confirmed (even if Light's says exudate)
  • Pleural fluid pH ≤7.2 = complicated parapneumonic → chest tube (mandatory) — the single most important decision point in parapneumonic effusions
  • RA effusion has the lowest pleural glucose (often <30 mg/dL, sometimes near 0) — classic board fact
  • Bilateral effusions + HF → treat with diuretics first, thoracentesis not initially required. Unilateral or atypical → always tap.
★ Memory Trick
Light's criteria: "An effusion is Exudative if ANY one of three ratios is met" "Protein >0.5, LDH ratio >0.6, LDH >2/3 ULN — any one = exudate" Parapneumonic pH: "pH 7.2 or less = Drain. pH above 7.2 = treat with ABx alone" "RA effusion has the lowest glucose of any effusion — it's the most hostile environment" HF Light's trap: "HF on diuretics → Light's may lie → check albumin gradient (>1.2 = transudate)"
Before you beginLung Cancer3 questions
Answer these three before you read the topic. Getting them wrong is expected and useful — attempting a question first is what makes the material below stick. Each explanation unlocks only after you submit.
Question 1 of 3 · Medium · Lung Cancer · USPSTF Screening Eligibility
Four asymptomatic adults present for preventive care. Which one meets USPSTF criteria for annual low-dose CT lung cancer screening?
Click to Reveal Answer
Correct answer: A — A 57-year-old who smoked one pack daily for 22 years and quit four years ago
USPSTF criteria, sometimes abbreviated A-50-80-20-15, are age 50 to 80, at least 20 pack-years, and currently smoking or having quit within the past 15 years. The 57-year-old satisfies all three: age in range, 22 pack-years, quit four years ago. Each distractor fails exactly one criterion, which is the discrimination the question is testing.
Why the other choices are wrong
  • A 48-year-old who smokes two packs daily and has a 28 pack-year history — Incorrect. Pack-years qualify comfortably at 28, but age 48 falls below the threshold of 50. Screening is not recommended outside the validated age window regardless of exposure intensity.
  • A 66-year-old with 35 pack-years who quit 19 years ago — Incorrect. Age and pack-years both qualify, but quitting 19 years ago exceeds the 15-year window. Screening is discontinued once a person has not smoked for 15 years, as risk has declined substantially.
  • A 72-year-old with 40 pack-years, still smoking, with metastatic pancreatic cancer on hospice — Incorrect. Smoking history qualifies, but screening stops when a health problem substantially limits life expectancy or the ability or willingness to undergo curative lung surgery. Screening only helps someone who could act on the result.
  • A 54-year-old never-smoker with 20 years of household secondhand smoke exposure — Incorrect. USPSTF eligibility rests on personal pack-years. Secondhand smoke, radon, asbestos, and family history all raise risk but do not by themselves confer screening eligibility under this recommendation.
Board pearlA-50-80-20-15: age 50–80, ≥20 pack-years, currently smoking or quit within 15 years, annual low-dose CT, USPSTF grade B. Two stop rules travel with it — 15 years of abstinence, or comorbidity precluding curative surgery. Pair every screening discussion with cessation counselling, and note what has no screening role: chest radiography and sputum cytology, both of which failed to reduce mortality.
Covered below under Module 6 — Lung Cancer
Question 2 of 3 · High Yield · Lung Cancer · Paraneoplastic SIADH
A 64-year-old man with 50 pack-years has four weeks of progressive weakness and confusion. Imaging shows a large central right hilar mass with bulky mediastinal adenopathy. Sodium 118 mEq/L, serum osmolality 250 mOsm/kg, urine osmolality 620 mOsm/kg, urine sodium 70 mEq/L. He is clinically euvolemic with normal renal, thyroid, and adrenal function. What is the most likely diagnosis?
Click to Reveal Answer
Correct answer: D — Small cell lung carcinoma producing ectopic ADH
The laboratory pattern defines SIADH: euvolemic hypotonic hyponatremia with inappropriately concentrated urine (osmolality 620, well above 100) and urine sodium above 30, with normal thyroid and adrenal function. Small cell lung carcinoma is the classic source of ectopic ADH, and the central hilar location with bulky adenopathy and rapid progression fits the histology precisely.
Why the other choices are wrong
  • Squamous cell carcinoma producing PTH-related peptide — Incorrect. PTHrP produces hypercalcemia, not hyponatremia. Squamous cell carcinoma is also typically central, so location alone cannot distinguish it — the electrolyte abnormality does.
  • Adenocarcinoma with an EGFR-activating mutation — Incorrect. EGFR mutation is a therapeutic target in adenocarcinoma, which is characteristically peripheral and more common in never-smokers and light smokers. It is not a mechanism of hyponatremia.
  • Bilateral adrenal metastases causing primary adrenal insufficiency — Incorrect, though genuinely tempting, since adrenal insufficiency does cause hyponatremia. The distinguishing features are that it produces hyponatremia with hyperkalemia and hypovolemia — and the stem explicitly specifies euvolemia and normal adrenal function.
  • Bronchial carcinoid tumor producing serotonin — Incorrect. Carcinoid syndrome presents with flushing, secretory diarrhea, wheezing, and right-sided valvular heart disease, not SIADH. Bronchial carcinoids can secrete ectopic ACTH, but serotonin does not cause hyponatremia.
Board pearlSort the paraneoplastic syndromes by histology, because that is how they are tested. Small cell — SIADH, ectopic ACTH (Cushing’s: rapid onset, hypokalemic metabolic alkalosis, hyperglycemia, hyperpigmentation, without the classic body habitus there has been no time to develop), and Lambert-Eaton myasthenic syndrome, in which proximal weakness paradoxically improves with repeated use. Squamous — PTHrP and hypercalcemia. Adenocarcinoma — hypertrophic pulmonary osteoarthropathy and clubbing. For the SIADH itself: fluid restriction first, and correct sodium no faster than 8 mEq/L per 24 hours to avoid osmotic demyelination.
Covered below under Module 6 — Lung Cancer
Question 3 of 3 · High Yield · Lung Cancer · Hypercalcemia Mechanism Trap
A 69-year-old man with 45 pack-years has a 4 cm cavitating central left upper lobe mass; biopsy confirms squamous cell carcinoma. Calcium 13.8 mg/dL, albumin 4.0 g/dL, phosphate 2.1 mg/dL, PTH 6 pg/mL, and 1,25-dihydroxyvitamin D low-normal. A bone scan is negative. What is the mechanism of his hypercalcemia?
Click to Reveal Answer
Correct answer: E — Tumor secretion of PTH-related peptide
This is humoral hypercalcemia of malignancy, and squamous histology is the signature — lung, head and neck, esophagus, cervix, and renal cell. PTHrP binds the PTH1 receptor, driving bone resorption and renal calcium reabsorption while causing renal phosphate wasting, and the resulting hypercalcemia suppresses native PTH. The low phosphate together with the suppressed PTH is the fingerprint.
Why the other choices are wrong
  • Ectopic PTH secretion by the tumor — Incorrect. True ectopic PTH secretion by a solid tumor is vanishingly rare, and the laboratory pattern would be the opposite of what is shown — PTH would be elevated, not suppressed at 6.
  • Osteolytic bone metastases releasing skeletal calcium — Incorrect, and this is the trap. The bone scan is negative, and the biochemistry points to a circulating humoral factor rather than local bone destruction. Local osteolytic hypercalcemia is characteristic of multiple myeloma, breast cancer, and lymphoma — and since PTH is suppressed in both mechanisms, the phosphate level and the bone scan are what separate them.
  • Tumor production of 1,25-dihydroxyvitamin D — Incorrect. Calcitriol-mediated hypercalcemia occurs in lymphoma and granulomatous disease such as sarcoidosis and tuberculosis. Here 1,25-dihydroxyvitamin D is low-normal, exactly as expected under PTHrP.
  • Coexisting primary hyperparathyroidism — Incorrect, though worth considering in an older patient, since hypercalcemia has more than one cause. Primary hyperparathyroidism produces hypercalcemia with an elevated or inappropriately normal PTH. A PTH of 6 is appropriately suppressed, which excludes it.
Board pearlLearn humoral hypercalcemia of malignancy as a four-part laboratory signature: high calcium, LOW phosphate, SUPPRESSED PTH, low or normal calcitriol — with a negative bone scan. Contrast it against primary hyperparathyroidism (PTH high, phosphate low) and calcitriol-mediated hypercalcemia (calcitriol high, seen in lymphoma and granulomatous disease). Treatment sequence: IV isotonic saline first, then a bisphosphonate such as zoledronic acid or denosumab, with calcitonin for rapid but short-lived control. Hypercalcemia of malignancy carries a poor prognosis, so it should also prompt a goals-of-care conversation.
Covered below under Module 6 — Lung Cancer
Tier 1
Domain 6 · High Yield
Module 6
Lung Cancer
👁 Free Preview
USPSTF Screening · Cell Types · Paraneoplastic Syndromes · Superior Vena Cava Syndrome
Why the PANCE Tests This

Lung cancer is the #1 cause of cancer death in the US. Boards test: USPSTF screening criteria, cell type characteristics (location, histology, paraneoplastic syndrome), and oncologic emergencies (SVC syndrome, hypercalcemia).

USPSTF Lung Cancer Screening — 2021 Guidelines
Annual Low-Dose CT (LDCT) Screening Criteria
  • Age 50–80 years (previously 55–80)
  • 20+ pack-year smoking history (previously 30+ pack-years)
  • Currently smoking OR quit within the past 15 years
  • All 3 criteria must be met
  • Discontinue screening if: quit smoking >15 years ago, develop comorbidity that would limit life expectancy or willingness for curative surgery, or age >80
Cell Types — The Board-Tested Characteristics
Cell TypeLocationClassic PresentationParaneoplastic SyndromeBoard Key
Adenocarcinoma (#1 overall)Peripheral, subpleuralOften asymptomatic initially. Non-smokers and women. Bronchoalveolar subtype (ground-glass opacity)Hypertrophic osteoarthropathy (clubbing)Most common lung cancer. Associated with EGFR, ALK, KRAS mutations → targeted therapy available.
Squamous Cell (#1 central)Central (hilar), near carinaHemoptysis, obstructive pneumonia, cavitating lesion, Pancoast tumor (superior sulcus)Hypercalcemia (PTHrP secretion) — most common PNS of squamous cellCavitating lesion + hypercalcemia = squamous cell
Small Cell (SCLC)Central, hilarRapid growth, early metastasis (brain, bone, liver, adrenal). Bulky mediastinal lymph nodes.SIADH (#1 PNS), Cushing's (ectopic ACTH), Lambert-Eaton syndrome, SCLC + anti-Hu antibodiesMost aggressive. Nearly always metastatic at diagnosis. Responds to chemo initially. NO surgery.
Large CellPeripheralLarge, rapidly growing. Non-specific presentation.Gynecomastia (β-hCG production)Diagnosis of exclusion after other cell types ruled out
Paraneoplastic Syndromes — The Most Tested
SyndromeTumor TypeMechanismBoard Key
SIADH (hyponatremia)SCLC (#1)Ectopic ADH productionHyponatremia + lung mass = SCLC until proven otherwise
HypercalcemiaSquamous cell (#1)PTHrP (parathyroid hormone-related protein)Cavitating mass + hypercalcemia = squamous cell
Cushing's syndromeSCLCEctopic ACTHRapidly progressive Cushing's features + lung mass
Lambert-Eaton Myasthenic SyndromeSCLCAnti-VGCC antibodies (P/Q type)Proximal muscle weakness that IMPROVES with repetition (opposite of MG)
Hypertrophic osteoarthropathyAdenocarcinoma, squamousUnknownPainful periosteal new bone formation + clubbing
Pancoast tumorSquamous cell (usually)Apical/superior sulcus tumor invading structuresShoulder/arm pain + Horner's syndrome (ptosis, miosis, anhidrosis) + ulnar neuropathy
Superior Vena Cava (SVC) Syndrome
  • Cause: Most common cause = lung cancer (especially SCLC) or lymphoma. Also mediastinal masses, thrombosis from central venous catheters.
  • Presentation: Facial swelling + arm edema + dilated neck/chest wall veins + dyspnea + headache. Worse with bending forward or lying down.
  • Diagnosis: CT chest with IV contrast — defines extent of obstruction.
  • Treatment: Radiation therapy (non-SCLC) or chemotherapy (SCLC) + steroids. Endovascular stenting for rapid symptom relief. NOT a surgical emergency requiring immediate decompression (unlike tension PTX).
⚑ Board Traps — Lung Cancer
  • USPSTF 2021 screening: age 50–80, 20+ pack-years, currently smoking or quit <15 years ago — NOT 55 or 30 pack-years (old criteria)
  • SCLC: NO surgery — chemotherapy is the backbone. SCLC is nearly always metastatic at diagnosis.
  • Lambert-Eaton: weakness IMPROVES with repetition (unlike MG where it WORSENS). Associated with SCLC.
  • Pancoast tumor (superior sulcus): Horner's syndrome (ptosis + miosis + anhidrosis) = cervical sympathetic chain involvement from apical tumor. Treat with concurrent chemoradiation + surgery.
  • Adenocarcinoma in a non-smoker — check EGFR, ALK, ROS1, KRAS mutations → may have targeted oral therapy available
  • SCLC + hyponatremia = SIADH from ectopic ADH — restrict fluids, consider tolvaptan for severe cases
★ Memory Trick
USPSTF Screening: "50-80, 20 pack-years, current or quit <15 years ago — all 3 required" Cell type locations: "Adenocarcinoma = Peripheral. Squamous = Central. SCLC = Central (and EVERYWHERE at diagnosis)" Paraneoplastic: "SCLC = SIADH + Cushing's + Lambert-Eaton. Squamous = HyperCalcemia." Lambert-Eaton: "Gets BETTER with exercise — OPPOSITE of myasthenia gravis (which gets WORSE)" Pancoast: "Apical tumor + Horner's syndrome (drooping eye, small pupil, dry face) + shoulder/arm pain"
Modules 7–12 · Extended Material · Access Code Required
Extended Pulmonary Topics
Tier 1
Domain 1 · Highest PANCE Weight
Module 7
Pulmonary Function Test Interpretation
FEV1/FVC · Obstructive vs Restrictive · TLC · DLCO · Pattern Recognition
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
The 5-Step PFT Approach
StepParameterFindingInterpretation
1FEV1/FVC<0.70 (or below LLN)Obstructive pattern → go to Step 3
1FEV1/FVCNormal (≥0.70)Not obstructive → go to Step 2
2FVCLow with normal FEV1/FVCPossible restrictive → MUST confirm with TLC
2FVCLow with low FEV1/FVCPossible mixed pattern → confirm TLC
3Bronchodilator response≥12% AND ≥200 mL FEV1 ↑Reversible → suggests asthma
3Bronchodilator responseMinimal changeIrreversible → suggests COPD
4TLC (full lung volumes)<80% predictedTRUE restrictive pattern confirmed
4TLC>120% predictedHyperinflation (emphysema, air trapping)
5DLCO (diffusing capacity)LowEmphysema, ILD, pulmonary vascular disease, anemia
5DLCONormalAsthma, chronic bronchitis (without emphysema)
5DLCOHighPulmonary hemorrhage, polycythemia, L→R shunt, obesity
Pattern Summary — The Most Tested Combinations
DiagnosisFEV1/FVCFVCTLCDLCO
Asthma↓Normal or ↓Normal or ↑Normal or ↑
COPD / Emphysema↓Normal or ↓↑ (hyperinflation)↓
Chronic Bronchitis↓Normal or ↓Normal or ↑Normal
Restrictive (ILD, obesity)Normal or ↑↓↓↓ (if ILD)
Neuromuscular (ALS, MG)Normal↓ (↓↓ supine)↓Normal
Mixed (COPD + ILD)↓↓↓Variable↓↓
⚑ Board Traps — PFTs
  • Restrictive disease CANNOT be diagnosed by spirometry alone — a low FVC with normal FEV1/FVC is only SUGGESTIVE of restriction. TLC measurement (full lung volumes) is required to confirm.
  • DLCO differentiates emphysema (low) from chronic bronchitis (normal) and asthma (normal/high) — the single most useful DLCO question on boards
  • Fixed ratio of 0.70 overdiagnoses COPD in elderly (normal aging reduces FEV1/FVC) and underdiagnoses in young — LLN is more accurate
  • Neuromuscular disease: FVC drops significantly from sitting to supine (>25% drop = diaphragm weakness). Normal DLCO helps distinguish from ILD.
  • Obesity hypoventilation (OHS): Restrictive pattern (low FVC, low TLC), normal DLCO, hypercapnia. BMI >30 + PaCO₂ >45 = OHS.
★ Memory Trick
PFT pattern: "FEV1/FVC low = Obstructive. FEV1/FVC normal + FVC low = Restrictive (confirm with TLC)" "You CANNOT diagnose restriction without TLC — spirometry only suggests it" DLCO: "Emphysema destroys alveoli → destroys gas exchange → DLCO drops. Bronchitis = normal walls = normal DLCO." Reversibility: "12% and 200mL = Asthma switch. Less than that = COPD"
Tier 1
Domain 2 · High PANCE Weight
Module 8 ★ Gap Added
Tuberculosis (TB)
Latent vs Active · RIPE Therapy · TST vs IGRA · Contact Tracing
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Why the PANCE Tests This

TB is tested every exam. Boards focus on: who to screen, TST vs IGRA interpretation, latent vs active distinction, RIPE therapy duration, and isolation precautions. High-yield because of public health implications.

Latent vs Active TB — The Critical Distinction
Latent TB Infection (LTBI)Active TB Disease
SymptomsNone — asymptomaticCough >3 weeks, night sweats, weight loss, hemoptysis, fever
CXRNormal or old granulomas/Ghon complexUpper lobe infiltrate, cavitation, lymphadenopathy
TST/IGRAPositive (hallmark of LTBI)Usually positive (but can be false-negative in immunocompromised)
Sputum AFB smearNegativePositive in pulmonary active TB
Contagious?NO — cannot transmitYES — airborne droplet nuclei. Requires airborne isolation (negative pressure room + N95)
Treatment goalPrevent progression to active diseaseCure and prevent transmission
Tuberculin Skin Test (TST) — Interpretation
Induration ThresholdPositive If…
≥5 mmHIV-positive; recent TB contact; organ transplant / immunosuppressed; CXR with old TB changes
≥10 mmHigh-risk occupations (healthcare workers, corrections, homeless); recent immigrants from high-prevalence countries; IV drug users; children <4 years; silicosis, DM, renal failure, malignancy
≥15 mmAny person with no known risk factors
  • IGRA (QuantiFERON-TB Gold / T-SPOT.TB): Blood test — preferred over TST when BCG vaccination history is present (BCG does NOT cause false-positive IGRA, but DOES cause false-positive TST)
  • Preferred LTBI screening test: IGRA for adults >5 years in the US (especially BCG-vaccinated immigrants)
Treatment
Active TB — RIPE Therapy
  • Rifampin + Isoniazid + Pyrazinamide + Ethambutol × 2 months (intensive phase)
  • Then Rifampin + Isoniazid × 4 months (continuation phase) = total 6 months
  • Drug-resistant TB (MDR-TB): Requires specialist consultation, 18–24 months, injectable agents
Latent TB — Treatment Options
  • Isoniazid (INH) × 9 months — traditional first-line (9H)
  • Isoniazid + Rifapentine × 3 months (weekly doses) — 3HP, preferred in most patients (high completion rate)
  • Rifampin × 4 months — alternative if INH contraindicated
  • Always give Pyridoxine (B6) with INH — prevents peripheral neuropathy
⚑ Board Traps — TB
  • BCG vaccination causes false-positive TST but NOT IGRA — use IGRA in BCG-vaccinated patients
  • Airborne isolation (negative pressure room + N95) required for suspected active pulmonary TB — NOT standard droplet precautions
  • INH toxicity: hepatotoxicity (#1) and peripheral neuropathy — always give pyridoxine (B6) with INH
  • Rifampin drug interactions: CYP450 inducer — reduces efficacy of warfarin, oral contraceptives, antiretrovirals. Causes orange discoloration of urine/secretions (benign, warn patients).
  • Ethambutol toxicity: optic neuritis — monitor visual acuity and color vision monthly
  • Pyrazinamide toxicity: hyperuricemia — can precipitate gout
  • Miliary TB: Hematogenous dissemination → diffuse bilateral "millet seed" nodules on CXR. Can cause meningitis, bone/joint infection, choroidal tubercles (ophthalmologic exam).
★ Memory Trick
Active TB treatment: "RIPE for 2 months, then RI for 4 months" = 6 months total Drug toxicities: "Rifampin = Red urine (benign). INH = Neuro (give B6) + Liver. Ethambutol = Eyes. Pyrazinamide = gout (uric acid)" TST thresholds: "5 for HIV/contacts/immunosuppressed. 10 for high-risk groups. 15 for everyone else." BCG trap: "BCG fools the TST but NOT the IGRA — use IGRA in immigrants" LTBI modern: "3HP (INH + Rifapentine weekly × 12 doses) = fastest, best adherence"
Tier 2
Domain 3 · Important & Gap Topics
Module 9 ★ Gap Added
Interstitial Lung Disease (ILD) & Idiopathic Pulmonary Fibrosis
Honeycombing · Restrictive Pattern · Antifibrotics · Velcro Crackles
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition
  • ILD = diffuse parenchymal lung diseases — heterogeneous group causing progressive fibrosis and/or inflammation
  • Classic presentation: Progressive exertional dyspnea + dry, non-productive cough + "Velcro" bibasilar crackles (coarse, late-inspiratory) + finger clubbing (in IPF)
  • PFTs: Restrictive pattern (↓FVC, ↓TLC, normal FEV1/FVC) + low DLCO (most sensitive early finding)
ILD — PANCE Classification

PANCE tests pattern recognition and initial management — not sub-typing of ILD patterns:

ILD TypeKey FeaturesTreatment
IPF (UIP pattern)Bilateral basilar honeycombing, traction bronchiectasis on HRCT. Older male smoker. Progressive.Nintedanib or pirfenidone. NO steroids (worsen IPF).
Hypersensitivity PneumonitisAntigen exposure (birds, mold, farmer's lung). Upper/mid lung. Reversible if antigen removed early.Remove antigen. Steroids for acute severe.
Sarcoidosis (pulmonary)Bilateral hilar adenopathy. Young Black woman. May be asymptomatic.Steroids if symptomatic or vital organ involved.
Drug-induced ILDAmiodarone, methotrexate, nitrofurantoin, bleomycin. History + exposure = key.Stop offending drug. Steroids if severe.
CTD-associated ILDRA, SLE, SSc. ILD may precede arthritis symptoms.Treat underlying CTD + specialist referral.

🩺 PANCE Pearl: IPF is the most tested ILD. The anti-fibrotic rule (nintedanib/pirfenidone) and the no-steroids rule are the two most tested facts.

IPF Treatment
  • Antifibrotic agents (slow progression): Nintedanib or Pirfenidone — slow FVC decline, do NOT reverse fibrosis
  • Supplemental oxygen if resting or exertional hypoxemia
  • Lung transplantation: Definitive treatment for eligible patients
  • Pulmonary rehabilitation
  • Corticosteroids are NOT beneficial in IPF — no evidence of benefit; may worsen by increasing infection risk
Diagnostic Approach
  • HRCT (High-Resolution CT): First-line imaging — shows typical patterns (UIP pattern in IPF: honeycombing, traction bronchiectasis, basal/subpleural predominance)
  • BAL (Bronchoalveolar Lavage): Rules out infection; lymphocytosis suggests HP or sarcoidosis
  • Surgical lung biopsy: Gold standard when HRCT is non-diagnostic; often avoided in elderly or frail patients
⚑ Board Traps — ILD
  • Low DLCO is the most sensitive early finding in ILD — may be abnormal before spirometry shows restriction
  • Honeycombing + subpleural basal distribution on HRCT = UIP pattern = IPF diagnosis — biopsy not needed if HRCT is typical
  • Corticosteroids do NOT help IPF — may benefit HP or CTD-ILD but not IPF
  • Asbestosis vs. Silicosis location: Asbestosis = LOWER lobes. Silicosis = UPPER lobes. Opposite of what you might expect.
  • Amiodarone toxicity: Bilateral interstitial infiltrates, phospholipidosis on biopsy. Treat by stopping amiodarone; steroids if severe.
Tier 2
Domain 3 · Important & Gap Topics
Module 10 ★ Gap Added
Sarcoidosis
Löfgren Syndrome · Bilateral Hilar Adenopathy · Non-Caseating Granulomas · ACE Level
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition Pattern
  • Demographics: African American women aged 20–40 most commonly. Also Scandinavian. Winter/spring clustering.
  • Classic presentation: Bilateral hilar lymphadenopathy (BHL) on CXR ± constitutional symptoms (fatigue, weight loss, fever)
  • Pulmonary: Dyspnea, dry cough. Upper/mid lobe predominance on imaging.
  • Labs: Elevated ACE level (50–80% sensitive), elevated calcium (hypercalciuria even if serum Ca2+ normal), elevated alkaline phosphatase
Systemic Manifestations — The Classic Boards Associations
SystemManifestationBoard Key
SkinErythema nodosum (tender red nodules on shins), Lupus pernio (violaceous facial plaques)Erythema nodosum in sarcoid = good prognosis
EyesAnterior uveitis (most common), posterior uveitis, optic neuritisScreen all sarcoid patients with slit-lamp exam
HeartCardiac sarcoid: Complete heart block, VT, sudden deathMost common cause of death from cardiac sarcoid = arrhythmia. Holter monitor + cardiac MRI.
Nervous systemFacial nerve palsy (CN VII most common), meningitis, hypothalamic dysfunctionNeurosarcoid = poor prognosis; treat aggressively
KidneyHypercalciuria → nephrolithiasis, nephrocalcinosisMechanism: granulomas produce excess 1,25-VitD
Löfgren SyndromeBHL + erythema nodosum + ankle periarthritis (± fever)EXCELLENT prognosis — spontaneous resolution in 85–90%. May not need steroids.
Diagnosis & Treatment
  • Gold standard: Biopsy showing non-caseating granulomas with exclusion of other causes (TB, fungal infection). Safest biopsy site: skin, peripheral lymph nodes, or endobronchial (EBUS-TBNA).
  • Löfgren syndrome: Clinical diagnosis — biopsy NOT required in classic presentation
  • First-line treatment: Oral corticosteroids (prednisone 20–40 mg/day) — for symptomatic pulmonary disease, cardiac, ocular, neurologic, or hypercalcemia
  • Steroid-sparing agents: Methotrexate, azathioprine, hydroxychloroquine (mild disease)
⚑ Board Traps — Sarcoidosis
  • Non-caseating granulomas = sarcoidosis. Caseating granulomas = TB — key histologic distinction
  • ACE level is NOT diagnostic — elevated in only 50–80%, and can be elevated in other granulomatous diseases
  • Löfgren syndrome = NO biopsy needed — classic clinical presentation is sufficient for diagnosis
  • Sarcoid hypercalcemia: Granulomas produce excess calcitriol (1,25-VitD) → hypercalciuria even with normal serum Ca2+. Avoid high-calcium diet and sunlight exposure.
  • Cardiac sarcoidosis: AV block in a young patient without obvious structural disease = think cardiac sarcoid. Confirmed with cardiac MRI (LGE) or FDG-PET.
★ Memory Trick
Sarcoid classic: "BHL + young Black woman + elevated ACE + non-caseating granulomas" Löfgren: "BHL + erythema nodosum + ankle arthritis = Löfgren = Lucky prognosis (self-resolves)" Granuloma distinction: "Non-caseating = Sarcoid. Caseating = TB." (Caseating = cheese-like = TB "caseation") Calcium: "Granulomas make vitamin D → calcium goes up → kidneys spill it → stones" Cardiac sarcoid: "Young person with heart block + no obvious cause = think sarcoid"
Tier 2
Domain 4 · High Yield
Module 11 ★ Gap Added
Pulmonary Hypertension & Cor Pulmonale
WHO Groups · RHC Diagnosis · Vasodilators · Cor Pulmonale Management
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition
  • Definition: Mean pulmonary artery pressure (mPAP) ≥20 mmHg at rest on right heart catheterization (RHC)
  • Classic presentation: Progressive exertional dyspnea (most common) → syncope → right heart failure (JVD, hepatomegaly, peripheral edema, ascites)
  • Signs: Loud P2 (pulmonic component), right-sided S3/S4, parasternal heave, TR murmur
  • EKG: Right axis deviation, RVH (R wave dominant in V1), P pulmonale (peaked P waves in II)
  • Echo (screening): Elevated RV systolic pressure, RV dilation/hypertrophy, flattening of interventricular septum ("D-shaped" LV). Definitive diagnosis = RHC.
WHO Classification — 5 Groups
GroupMechanismCommon CausesTreatment Approach
Group 1 — PAHArterial/pre-capillaryIdiopathic, heritable, connective tissue disease (SSc), HIV, portal HTN, drugs (cocaine, meth, anorexigens)Targeted PAH therapy (see below)
Group 2 — Left heart diseasePost-capillary (elevated PCWP)HFpEF, HFrEF, valvular diseaseTreat underlying heart disease — PAH-specific drugs NOT indicated
Group 3 — Lung diseaseHypoxia-drivenCOPD, ILD, OSA, hypoxiaTreat underlying lung disease, supplemental O₂
Group 4 — CTEPHChronic thromboembolic obstructionUnresolved PE → organized thrombusPulmonary endarterectomy (curative if accessible) or riociguat
Group 5 — MultifactorialUnclear/multifactorialSarcoid, sickle cell, metabolic disordersTreat underlying cause
PAH-Specific Treatment (Group 1 Only)
  • Endothelin receptor antagonists (ERAs): Ambrisentan, bosentan, macitentan — vasodilators + antiproliferative
  • PDE5 inhibitors: Sildenafil, tadalafil — vasodilators. Note: contraindicated with nitrates (severe hypotension)
  • Prostacyclin analogs: Epoprostenol (IV, most potent, continuous infusion), treprostinil, iloprost (inhaled)
  • sGC stimulator: Riociguat — also used for CTEPH (Group 4)
  • Vasoreactivity testing (nitric oxide challenge): ~10% of Group 1 patients respond → treat with CCBs (amlodipine, nifedipine, diltiazem). Only these patients benefit from CCBs.
Cor Pulmonale
  • Definition: Right ventricular hypertrophy and/or failure due to pulmonary hypertension from lung disease (Group 3)
  • Most common cause: COPD
  • Signs: JVD, peripheral edema, hepatomegaly, parasternal heave, loud P2
  • Management: Treat underlying lung disease, LTOT (if hypoxemic), diuretics for volume overload, anticoagulation if PE suspected
  • Avoid vasodilators (nitrates, CCBs) in cor pulmonale without proper testing — can cause systemic hypotension and worsen RV perfusion
⚑ Board Traps — Pulmonary HTN
  • Definitive diagnosis requires right heart catheterization (RHC) — echo is screening only
  • PAH-specific drugs (ERAs, PDE5i, prostacyclins) are ONLY for Group 1 PAH — NOT for Group 2 (left heart) or Group 3 (lung disease)
  • Group 2 (HF-related PH): PAH drugs may be HARMFUL — can worsen pulmonary edema by increasing pulmonary blood flow into a failing left heart
  • CTEPH is potentially curable with pulmonary endarterectomy — don't miss this diagnosis in patients with prior PE and persistent PH
  • Sildenafil + nitrates = absolute contraindication (both cause vasodilation → profound hypotension)
Tier 1
Domain 5 · High Yield
Module 12
Pneumothorax
Primary vs Secondary · Tension PTX · Needle Decompression · Chest Tube · Recurrence
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition
TypeClassic PatientKey FeatureManagement
Primary SpontaneousTall, thin young male, no lung diseaseRupture of apical blebs. Sudden pleuritic pain + dyspnea. Well-tolerated.Small (<2cm): observation + O₂. Large/symptomatic: needle aspiration or small-bore chest tube.
Secondary SpontaneousCOPD, ILD, PCP — underlying lung diseasePoorly tolerated — limited pulmonary reserve. Higher morbidity.Lower threshold for chest tube. Do NOT observe — these patients decompensate.
TraumaticPost-trauma (MVA, rib fractures, penetrating)May have hemothorax (hemopneumothorax)Chest tube (large-bore for hemopneumothorax)
IatrogenicPost-central line, thoracentesis, ventilatorMay be small if procedure-relatedChest tube if on positive pressure ventilation (mandatory)
TensionAny — trauma, mechanical ventilationMediastinal shift AWAY from PTX, tracheal deviation, JVD, hypotension, absent breath soundsIMMEDIATE needle decompression (14-16G, 2nd ICS, MCL) then chest tube. DO NOT wait for CXR.
Tension Pneumothorax — The Emergency
⚑ Tension PTX = Clinical Diagnosis — DO NOT Wait for CXR
  • Mechanism: One-way valve — air enters pleural space on inspiration but cannot escape → progressive pressure → mediastinal shift → kinks great vessels → circulatory collapse
  • Classic triad: Absent breath sounds unilaterally + tracheal deviation AWAY from affected side + hypotension
  • Immediate treatment: Needle decompression — 14–16 gauge needle, 2nd intercostal space, midclavicular line (or 4th/5th ICS anterior axillary line in obese) → immediately followed by chest tube
  • On mechanical ventilation: Sudden ↑ peak airway pressures + ↓ O₂ saturation + hypotension = tension PTX. Disconnect from ventilator, needle decompress.
⚑ Board Traps — Pneumothorax
  • Tension pneumothorax is a CLINICAL diagnosis — do NOT wait for CXR. Hemodynamic instability + absent breath sounds + tracheal deviation = needle decompress NOW.
  • Supplemental oxygen accelerates PTX reabsorption — increases nitrogen gradient. Give high-flow O₂ even if patient is not hypoxic.
  • Patients on positive-pressure ventilation with any pneumothorax require chest tube — observation is NOT safe (risk of tension PTX).
  • Recurrence of primary spontaneous PTX is ~30% after first episode → consider pleurodesis or VATS after second episode (or first if high-risk occupation: pilot, diver)
  • Secondary spontaneous PTX: COPD patients — lower threshold for intervention. These patients cannot compensate even for small PTX.
  • Needle decompression site: 2nd ICS, MCL (preferred) or 4th/5th ICS, anterior axillary line (alternative in obese)
★ Memory Trick
Tension PTX: "Trachea runs AWAY from trouble" — deviation AWAY from the PTX side "Needle decompress, then tube — never wait for the X-ray if the patient is crashing" PTX on vent: "Peak pressures up + O₂ down + BP down = tension PTX — disconnect ventilator first" Supplemental O₂ for PTX: "Nitrogen washout accelerates reabsorption — give O₂ even if not hypoxic" Recurrence after first primary PTX: "30% chance — warn the patient. Second PTX = pleurodesis conversation."
🔒 Full Bootcamp Access

You've seen the preview.
Unlock all 17 Pulmonary topics.

These 2 topics are free — a real look at how we teach. The remaining 15 topics below, along with interactive diagrams, EKG popups, Module D differentials, Module E board pearls, and audio mnemonics, are included with bootcamp enrollment.

Everything in the full Pulmonary syllabus
17 fully-worked clinical topics
Interactive SVG anatomy diagrams
Module D — must-know differentials
Module E — domain board pearls
Animated EKG strips & 12-lead viewer
Audio mnemonics per topic
20 PANCE-style board questions
Clinical vignettes + teaching pearls
🔒 Pulmonary Function Test Interpretation 🔒 Tuberculosis (TB) 🔒 Interstitial Lung Disease & IPF 🔒 Sarcoidosis 🔒 Pulmonary Hypertension & Cor Pulmonale 🔒 Pneumothorax 🔒 Acute Respiratory Distress Syndrome (ARDS) 🔒 Obstructive Sleep Apnea (OSA) 🔒 Cystic Fibrosis 🔒 Pertussis & Acute Bronchitis + 1 more topics
Enroll in Bootcamp  → Learn More
📚5 complete systems
🎯Pre & post-rotation assessment
📟Full EKG library
🩺84 clinical vignettes
👨‍⚕️Dr. Rajiv Choudhary, MD MPH
✅ Full Access Unlocked — Pulmonary Bootcamp
🔑
Have an access code?
Enter your bootcamp access code to unlock the full syllabus.
❌ Incorrect code — check with your instructor
or
Don't have a code? Enroll in the bootcamp →
Blueprint Gap Topics · Added 2025
ARDS · Obstructive Sleep Apnea · Cystic Fibrosis · Pertussis & Acute Bronchitis · Pneumoconiosis
Topics present on the 2025 NCCPA PANCE Blueprint not covered in prior modules — now fully integrated
Tier 1
Blueprint Gap Topic · Added 2025
Module 13 ★ Gap Added
Acute Respiratory Distress Syndrome (ARDS)
Berlin Criteria · P:F Ratio · Lung-Protective Ventilation · Prone Positioning · Neuromuscular Blockade
★★★ PANCE PriorityTidal Volume Trap
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition Pattern
  • Mechanism: Diffuse alveolar injury → increased capillary permeability → protein-rich non-cardiogenic pulmonary edema → shunt physiology with poor compliance
  • Most common precipitant: Sepsis. Then aspiration, pneumonia, multi-trauma, acute pancreatitis, massive transfusion (TRALI), near-drowning, inhalation injury
  • Clinical picture: Refractory hypoxemia developing over hours to days, diffuse bilateral infiltrates, and falling compliance that forces rising ventilator pressures
  • What it is not: Cardiogenic pulmonary edema. Filling pressures are normal — echocardiography is the practical way to exclude cardiac origin when no ARDS risk factor is obvious.
Berlin Definition — All Four Required
CriterionRequirementBoard Key
TimingWithin 1 week of a known insult or of new / worsening respiratory symptomsChronic fibrosis does not qualify
ImagingBilateral opacities not fully explained by effusion, lobar collapse, or nodulesChest radiograph or CT both acceptable
Origin of edemaNot fully explained by cardiac failure or fluid overloadObjective assessment (echo) needed when no risk factor is present
OxygenationPaO₂/FiO₂ measured on PEEP ≥5 cmH₂OWithout PEEP ≥5 the ratio cannot be used to stage
Severity by P:F Ratio (on PEEP ≥5)
SeverityPaO₂/FiO₂Implication
Mild200–300Selected patients manageable with non-invasive support
Moderate100–200Higher-PEEP strategy; prone positioning once the ratio falls below 150
Severe≤100Prone positioning, consider neuromuscular blockade, ECMO referral if refractory
Management — What Actually Changes Mortality
  • Lung-protective ventilation (mortality benefit): Tidal volume 6 mL/kg of PREDICTED body weight, plateau pressure ≤30 cmH₂O, with permissive hypercapnia tolerated to a pH of roughly 7.20–7.25
  • Prone positioning (mortality benefit): 12–16 hours per day when PaO₂/FiO₂ is under 150 (PROSEVA)
  • Conservative fluid strategy: Improves oxygenation and ventilator-free days; no independent mortality benefit (FACTT)
  • Neuromuscular blockade: Cisatracurium reserved for severe disease with ventilator dyssynchrony — routine early paralysis is not supported (ROSE)
  • ECMO: Consider for refractory severe hypoxemia at an experienced center
  • Corticosteroids: Clear benefit in COVID-19-associated ARDS (dexamethasone); still debated for other causes
  • No mortality benefit: Inhaled nitric oxide (transient oxygenation gain only), routine pulmonary artery catheter, and raising tidal volume to normalize CO₂
⚑ Board Traps — ARDS
  • Tidal volume is dosed on PREDICTED body weight, derived from height and sex — never actual weight. An obese patient does not receive a larger tidal volume.
  • Do not raise tidal volume to correct a rising CO₂. Permissive hypercapnia is the accepted trade-off, because ventilator-induced lung injury kills and a pH of 7.22 does not.
  • The P:F ratio only counts on PEEP ≥5 — a ratio quoted on room air cannot stage ARDS
  • Prone positioning carries a mortality benefit; neuromuscular blockade and inhaled nitric oxide do not. This is the pair most often reversed.
  • ARDS versus cardiogenic edema: ARDS has normal filling pressures. Bilateral infiltrates with a raised BNP and an S3 point to heart failure instead.
  • Bilateral infiltrates within 6 hours of transfusion is TRALI — a recognized ARDS precipitant, and distinct from simple volume overload (TACO)
★ Memory Trick
Berlin, four boxes: "1 week · Bilateral · not Cardiac · P:F on PEEP ≥5" Severity: "300 – 200 – 100" — mild, moderate, severe, as the ratio falls and the lung stiffens Ventilator settings: "6 and 30" — 6 mL/kg predicted body weight, plateau ≤30 What saves lives: "Small breaths and face down." Paralysis and nitric oxide do not.
Tier 1
Blueprint Gap Topic · Added 2025
Module 14 ★ Gap Added
Obstructive Sleep Apnea (OSA)
AHI Thresholds · Epworth Scale · Polysomnography · CPAP · Cardiovascular Consequences · Obesity Hypoventilation
★★★ PANCE PriorityPediatric Treatment Trap
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition Pattern
  • Mechanism: Repetitive pharyngeal collapse during sleep → apneas and hypopneas → intermittent hypoxemia, sympathetic surges, and arousals that fragment sleep architecture
  • Risk factors: Obesity and increased neck circumference, male sex, advancing age, retrognathia, adenotonsillar hypertrophy (the dominant cause in children), alcohol and sedatives, hypothyroidism, acromegaly
  • Nocturnal symptoms: Loud snoring, witnessed apneas, gasping or choking arousals, nocturia
  • Daytime symptoms: Non-restorative sleep, morning headache, excessive daytime sleepiness, impaired concentration, and a materially raised motor vehicle collision risk
  • Screening tools: STOP-BANG, and the Epworth Sleepiness Scale (above 10 indicates excessive sleepiness; 16 or more is severe)
Severity by Apnea-Hypopnea Index (events per hour)
AHISeverityTreatment implication
Under 5NormalNo OSA
5–15MildTreat if symptomatic, or if cardiovascular comorbidity is present
15–30ModerateCPAP indicated
Over 30SevereCPAP indicated regardless of symptoms
Diagnosis
  • In-laboratory polysomnography is the gold standard, and is required whenever comorbidity clouds the picture — heart failure, COPD, neuromuscular disease, or suspected central apnea or hypoventilation
  • Home sleep apnea testing is acceptable for uncomplicated patients with a high pretest probability. A negative home study in a symptomatic patient does not exclude OSA and must be followed by polysomnography.
  • Epworth measures sleepiness, not severity. The AHI defines severity, and the two correlate poorly — a patient can have severe OSA and a modest Epworth score.
Cardiovascular and Metabolic Consequences
  • Resistant hypertension — OSA is the most common identifiable cause, driven by hypoxia-induced sympathetic surges
  • Atrial fibrillation — untreated OSA sharply raises recurrence after cardioversion or ablation
  • Pulmonary hypertension — WHO Group 3, with cor pulmonale in advanced disease
  • Also: Stroke, coronary disease, insulin resistance, and nocturnal sudden cardiac death clustering in the early morning hours
Treatment
  • CPAP is first-line for moderate-to-severe disease and for symptomatic mild disease. Adherence is the limiting factor, so address it before declaring failure.
  • Behavioral: Weight loss (curative in some), positional therapy, and avoiding alcohol and sedatives near bedtime
  • Mandibular advancement device: Mild-to-moderate disease, or CPAP intolerance
  • Hypoglossal nerve stimulation: Selected CPAP-intolerant patients meeting anatomic criteria
  • Children: adenotonsillectomy is first-line, because adenotonsillar hypertrophy is the usual cause
  • Residual sleepiness on adherent CPAP: Modafinil or solriamfetol, after re-checking adherence data and pressure settings
  • Obesity hypoventilation syndrome: BMI 30 or above with an awake PaCO₂ above 45 mmHg and no alternative explanation. Frequently coexists with OSA, often needs bilevel rather than CPAP, and weight reduction is definitive.
⚑ Board Traps — OSA
  • A child with OSA gets the tonsils and adenoids out, not CPAP — the most reliable pediatric pulmonary trap on this topic
  • Daytime hypercapnia is not explained by OSA alone. An awake PaCO₂ above 45 in an obese patient means obesity hypoventilation syndrome, which changes both the device and the prognosis.
  • OSA is the most common identifiable cause of resistant hypertension — screen before escalating to a fourth antihypertensive
  • CPAP lowers blood pressure only modestly and never substitutes for antihypertensive therapy
  • A negative home sleep study does not rule out OSA — it under-detects, so a symptomatic patient proceeds to polysomnography
  • Screen before elective surgery. Undiagnosed OSA raises perioperative airway and opioid risk, which is precisely what STOP-BANG exists for.
★ Memory Trick
AHI severity: "5 · 15 · 30" — mild, moderate, severe Treatment by age: "Kids lose the tonsils, adults get the mask." Epworth versus AHI: "Epworth says how sleepy. AHI says how bad." They disagree constantly. Resistant hypertension: "Ask about snoring before adding a fourth drug."
Tier 2
Blueprint Gap Topic · Added 2025
Module 15 ★ Gap Added
Cystic Fibrosis
CFTR Mutation · ΔF508 · Sweat Chloride · Pseudomonas Colonization · ABPA · CFTR Modulators · Pancreatic Insufficiency
★★ High YieldDiagnostic Test Trap
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition Pattern
  • Genetics: Autosomal recessive, CFTR gene on chromosome 7, with ΔF508 (F508del) the commonest mutation. It is the most common lethal inherited disease in people of Northern European ancestry.
  • Mechanism: Defective CFTR chloride and bicarbonate transport → dehydrated viscous secretions → obstruction, chronic infection, and progressive organ damage
  • Newborn: Meconium ileus (10–20%, and essentially pathognomonic), prolonged cholestatic jaundice
  • Infant and child: Failure to thrive despite a good appetite, steatorrhea, recurrent sinopulmonary infection, nasal polyps, rectal prolapse
  • Adolescent and adult: Bronchiectasis with chronic productive cough and hemoptysis, pancreatic insufficiency, CF-related diabetes, distal intestinal obstruction syndrome, and male infertility
Diagnosis
TestResultInterpretation
Newborn screenElevated immunoreactive trypsinogenA screen, not a diagnosis — always confirm
Sweat chloride≥60 mmol/LDiagnostic. This is the confirmatory test.
Sweat chloride30–59 mmol/LIntermediate — proceed to CFTR genotyping
Sweat chlorideUnder 30 mmol/LNormal; CF unlikely
CFTR genotypingTwo disease-causing variantsConfirms the diagnosis and, critically, selects the modulator
Airway Microbiology Shifts With Age
  • Infancy and early childhood: Staphylococcus aureus and Haemophilus influenzae
  • Later childhood onward: Pseudomonas aeruginosa — chronic colonisation marks a clear inflection in lung function decline and prognosis
  • Burkholderia cepacia complex: Accelerated decline, and at many centers a contraindication to transplantation. Requires strict infection-control segregation.
  • Allergic bronchopulmonary aspergillosis (ABPA): Suspect when a patient deteriorates despite good therapy with a rising total IgE and Aspergillus-specific IgE. Treat with corticosteroids plus itraconazole — not with more antibacterials.
Management
  • Airway clearance: Chest physiotherapy, inhaled hypertonic saline, and dornase alfa (recombinant human DNase) to reduce sputum viscosity
  • Chronic suppression: Inhaled tobramycin for established Pseudomonas; chronic azithromycin for its anti-inflammatory effect
  • CFTR modulators — the transformative change: ivacaftor is a potentiator for gating mutations such as G551D, while elexacaftor / tezacaftor / ivacaftor covers F508del and now treats the large majority of patients. Therapy is genotype-directed, which is why genotyping matters well beyond diagnosis.
  • Nutrition: Pancreatic enzyme replacement with meals, a high-calorie diet, and supplementation of the fat-soluble vitamins A, D, E and K
  • Exacerbation: Intravenous antipseudomonal therapy, conventionally two agents of different classes, guided by sputum sensitivities
  • Advanced disease: Referral for lung transplantation
⚑ Board Traps — Cystic Fibrosis
  • Sweat chloride is the confirmatory test, not genetic testing. Genotyping follows, and its principal job is choosing the modulator.
  • Nasal polyps in a child should prompt a CF evaluation — they are rare in otherwise healthy children
  • Male infertility is obstructive: congenital bilateral absence of the vas deferens affects roughly 98%, while spermatogenesis is normal — so fatherhood is achievable with sperm retrieval
  • Match the vitamin to its deficiency syndrome: A → night blindness, D → osteopenia, E → neuropathy and hemolysis, K → coagulopathy
  • Deterioration despite optimal therapy with a rising total IgE is ABPA, and it needs corticosteroids rather than escalating antibacterials
  • Failure to thrive with a voracious appetite and greasy stools is pancreatic insufficiency, not inadequate intake
★ Memory Trick
Genetics: "CFTR sits on 7, and ΔF508 is the one to know." Confirmation: "Sweat the diagnosis — chloride 60 or more." Vitamins: "ADEK" — the fat-soluble four that vanish without enzymes. Organisms: "Staph first, Pseudomonas forever." Cepacia is the one that costs a transplant.
Tier 2
Blueprint Gap Topic · Added 2025
Module 16 ★ Gap Added
Pertussis & Acute Bronchitis
Whooping Cough Stages · Lymphocytosis · Azithromycin · Vaccine Prevention · Bronchitis — Viral, No Antibiotics
★★ High YieldAntibiotic Stewardship Trap
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Pertussis — Core Recognition Pattern
  • Organism: Bordetella pertussis, a gram-negative coccobacillus whose injury is toxin-mediated — which is exactly why antibiotics alter transmission far more than they alter symptoms
  • Hallmark laboratory finding: Marked absolute lymphocytosis, often above 10,000/µL, with the degree tracking severity in infants. It is lymphocytosis, not a neutrophil-predominant leukocytosis.
  • Usually afebrile or barely febrile despite a dramatic cough — a useful discriminator from pneumonia
  • Infants under 6 months are the danger group: they may present with apnea and cyanosis and never produce a whoop. They carry nearly all the mortality and usually require admission.
  • Complications: Secondary pneumonia, seizures, encephalopathy, rib fracture and pneumothorax from coughing, and refractory pulmonary hypertension with extreme leukocytosis in infants
The Three Stages
StageDurationFeaturesBoard key
Catarrhal1–2 weeksIndistinguishable from a common cold — coryza, mild cough, minimal feverMOST contagious, and the only window in which treatment alters the course
Paroxysmal2–6 weeksStaccato coughing fits, inspiratory whoop, post-tussive emesis, exhaustion between paroxysmsDiagnosis is usually made here — too late to shorten the illness
ConvalescentWeeks to monthsGradually waning coughThe "100-day cough"
Diagnosis and Treatment
  • Testing: Nasopharyngeal PCR is the test of choice and performs best within the first 3–4 weeks of cough. Culture is highly specific but slow and insensitive. Serology is reserved for late presentation.
  • Treatment: A macrolide, with azithromycin preferred. Treat within 3 weeks of cough onset, extended to 6 weeks in infants and in pregnancy.
  • Neonates: Azithromycin specifically, because erythromycin is associated with hypertrophic pyloric stenosis in infants under 1 month
  • Post-exposure prophylaxis: The same macrolide for close contacts regardless of vaccination status
  • Prevention: DTaP in the childhood series with Tdap boosters, plus Tdap in every pregnancy at 27–36 weeks, so maternal antibody crosses to protect the newborn before its own immunisation
Acute Bronchitis — The Stewardship Half of This Card
  • Almost always viral: Rhinovirus, influenza, coronaviruses, RSV, adenovirus, parainfluenza
  • Presentation: Cough with or without sputum for up to 3 weeks, often with transient bronchial hyperreactivity, and a normal chest radiograph
  • Antibiotics are not indicated — among the most frequently tested antibiotic-stewardship points on the exam
  • Management: Symptomatic care, with a bronchodilator only where there is genuine wheeze or airflow limitation
  • When to reconsider: A cough beyond 2–3 weeks with paroxysms, whoop, or post-tussive emesis should trigger pertussis testing rather than another antibiotic course
⚑ Board Traps — Pertussis & Bronchitis
  • Purulent sputum does not mean bacterial infection in acute bronchitis — the color reflects shed cells, not organisms, and is not a reason to prescribe
  • An infant with apnea and no whoop can still have pertussis. Waiting for the classic sound in a young infant is how this diagnosis gets missed.
  • Erythromycin in a neonate risks pyloric stenosis — use azithromycin
  • Antibiotics started in the paroxysmal stage reduce spread, not duration. Treat anyway for public-health reasons, but do not promise symptom relief.
  • Expect lymphocytosis, not neutrophilia. A neutrophil-predominant count should redirect you toward bacterial pneumonia.
  • Prophylax close contacts even when fully vaccinated — immunity wanes, which is why adolescent and adult cases occur at all
★ Memory Trick
Stages: "Catarrhal is Contagious → Paroxysmal is the Whoop → Convalescent is the 100-day cough." Treatment timing: "Antibiotics stop the spread, not the cough." Neonates: "Azithro for the newborn — erythro brings pyloric stenosis." Bronchitis: "Normal film, viral cause, no prescription."
Tier 2
Blueprint Gap Topic · Added 2025
Module 17 ★ Gap Added
Pneumoconiosis — Occupational Lung Diseases
Silicosis · Asbestosis · Coal Workers' Pneumoconiosis · Berylliosis · Byssinosis
★★ High YieldLobe Distribution Trap
🔒
Full content locked
Enter your bootcamp access code below to unlock all topic cards, clinical pearls, vignettes, and board traps.
Core Recognition Pattern
  • Definition: Interstitial lung disease caused by inhaled inorganic dust, with a latency measured in years to decades between exposure and disease
  • The exam always supplies the occupation — the history is the diagnostic test, so read it first
  • Physiology: Restrictive pattern with reduced DLCO — except byssinosis, which is obstructive
  • No therapy reverses established fibrosis. Management is removal from exposure, smoking cessation, influenza and pneumococcal vaccination, oxygen where indicated, surveillance for the associated malignancies, and transplant referral in advanced disease.
The Five to Know
DiseaseExposureImagingKey association
SilicosisMining, quarrying, sandblasting, foundry work, engineered-stone countertop fabricationUpper-lobe nodules; eggshell calcification of hilar nodes; progressive massive fibrosisMarkedly raised tuberculosis risk — screen annually. Also lung cancer, rheumatoid arthritis (Caplan), scleroderma.
AsbestosisShipbuilding, insulation, pipefitting, brake linings, demolition of older buildingsLower-lobe fibrosis; pleural plaques, often calcified on the diaphragmMesothelioma and bronchogenic carcinoma
Coal workers' pneumoconiosisCoal mining ("black lung")Upper-lobe nodules; progressive massive fibrosisCaplan syndrome (pneumoconiosis + rheumatoid arthritis + lung nodules). Unlike silica, it does not raise tuberculosis risk.
BerylliosisAerospace, electronics, alloy and nuclear industriesHilar adenopathy with upper-lobe granulomas — radiographically mimics sarcoidosisThe beryllium lymphocyte proliferation test distinguishes it; unusually among these, it responds to corticosteroids
ByssinosisCotton, flax and hemp textile processingUsually unremarkable — the abnormality is physiologicObstructive, with chest tightness on returning to work that eases across the week — "Monday chest tightness"
Asbestos — Separating the Two Cancers
  • Mesothelioma: Arises from pleura (occasionally peritoneum) with a latency of 20–40 years, and the risk is not increased by smoking. Presents with a unilateral pleural effusion, chest pain and dyspnea.
  • Bronchogenic carcinoma: The commoner asbestos-related malignancy overall, and its risk is multiplicative with smoking — which makes cessation the single highest-value intervention in an exposed smoker
  • Pleural plaques signal exposure, not disease. Isolated plaques are benign, do not impair function, and do not by themselves establish asbestosis.
⚑ Board Traps — Pneumoconiosis
  • Lobe distribution is the fastest discriminator: silica and coal go UP, asbestos goes DOWN
  • Silicosis obliges tuberculosis surveillance. Impaired macrophage function raises risk substantially, and silicotuberculosis is a recognized entity. Coal dust carries no comparable association.
  • Smoking multiplies bronchogenic carcinoma risk in asbestos exposure but does not raise mesothelioma risk — the pair most often reversed on this topic
  • Pleural plaques alone are not asbestosis and need no treatment; asbestosis means parenchymal fibrosis
  • Berylliosis is the sarcoidosis mimic. Non-caseating granulomas with hilar adenopathy in an aerospace or electronics worker should prompt the beryllium lymphocyte proliferation test before settling on sarcoidosis.
  • Byssinosis is obstructive, not restrictive, and the Monday-morning pattern of symptoms is the giveaway
  • A young engineered-stone countertop worker with upper-lobe fibrosis is silicosis — an emerging occupational epidemic and increasingly examinable
★ Memory Trick
Distribution: "Silica and Coal rise to the top; Asbestos sinks to the bottom." Silica: "Eggshell nodes — and always ask about TB." Asbestos cancers: "Smoking multiplies the lung cancer. Mesothelioma does not care whether you smoke." Caplan: "Pneumoconiosis + Rheumatoid arthritis + nodules." Byssinosis: "Monday tightness in the cotton mill — obstructive, not restrictive."
Module D · Must-Know Differentials
High-Yield Differentials & Distinguishing Features
The following differentials represent the highest-frequency diagnostic challenges in pulmonary medicine on the PANCE/PANRE. Each framework identifies the single pivotal feature that separates one diagnosis from another — the exact skill boards reward.
Tier 1
Differential D-1
Acute Dyspnea — Obstructive vs Infectious vs Vascular vs Cardiac
Asthma · COPD · PE · Pneumonia · Pneumothorax · ADHF · ARDS
★★★ Most-Tested DifferentialMultiple Lethal Traps
The Pivotal First Branch Points
  • Step 1 — Is it obstructive? Expiratory wheeze + reversibility = asthma. Fixed obstruction + smoking history + barrel chest = COPD. Both have wheeze — the reversibility and context separate them.
  • Step 2 — Is it infectious? Fever + focal consolidation + productive cough = pneumonia. Night sweats + weight loss + upper lobe + immigrant = TB. Immunocompromised + bilateral ground-glass = PCP.
  • Step 3 — Is it vascular? Sudden onset + pleuritic pain + risk factors + no fever = PE until ruled out. Bilateral wheeze + history of HF + JVD + orthopnea = cardiac asthma (HF).
  • Step 4 — Is it mechanical? Sudden pleuritic pain + absent breath sounds + tracheal deviation = pneumothorax. Hemodynamic collapse + tracheal deviation = tension PTX — treat immediately.
Distinguishing Feature Table — Acute Dyspnea
DiagnosisKey FeatureDistinguishing Sign/TestCannot Miss
AsthmaEpisodic wheeze, nocturnal cough, atopy, triggers≥12% + ≥200mL FEV1 reversibility post-BD; eosinophiliaSilent chest = impending arrest, NOT improvement
COPD ExacerbationSmoker, barrel chest, pursed-lip breathing, fixed obstructionLow FEV1/FVC not fully reversible; hyperinflation on CXRRising PaCO₂ = fatigue; target SpO₂ 88–92%, not 100%
Pulmonary EmbolismSudden onset, pleuritic, tachycardia, risk factors, no fever initiallyWells score → D-dimer or CTPA; S1Q3T3 on EKG (insensitive)Massive PE: SBP <90 = fibrinolytics, not anticoagulation alone
Community-Acquired PneumoniaFever, productive cough, focal consolidation, dullness to percussionCXR lobar consolidation; Gram stain + culture; WBC elevatedAspiration: dependent lobes (RLL upright, RUL supine)
Tension PneumothoraxTrauma/mechanical vent + absent breath sounds + tracheal deviation AWAYClinical diagnosis — hypotension + JVD + absent soundsDO NOT get CXR — needle decompress immediately
Acute HF (Cardiac Asthma)Orthopnea, PND, JVD, S3 gallop, bilateral cracklesBNP >400; CXR: cardiomegaly + Kerley B + bilateral effusionsBNP <100 effectively rules out HF as cause of dyspnea
ARDSBilateral infiltrates + hypoxia + recent trigger (sepsis, aspiration, trauma)PaO₂/FiO₂ <300; PCWP normal (not cardiogenic)Tidal volume 6 mL/kg IBW; plateau pressure <30 cmH₂O
⚑ Board Traps — Acute Dyspnea Differential
  • Cardiac asthma (HF) causes wheeze — bilateral wheeze does NOT always mean asthma or COPD. BNP, orthopnea, and JVD distinguish. Giving bronchodilators alone to cardiac asthma delays life-saving diuresis.
  • Normal CXR does NOT rule out PE — 30% of PEs have a normal chest X-ray. Normal CXR + dyspnea + tachycardia + risk factors = high PE suspicion.
  • COPD exacerbation + O₂ to 99% = hypercapnic respiratory failure in CO₂ retainers. Target 88–92%, not high-flow.
  • PCP in HIV looks just like ARDS — bilateral ground-glass infiltrates, hypoxia, normal or near-normal CXR early. CD4 <200 + bilateral GGO = PCP until proven otherwise.
  • ARDS vs cardiogenic pulmonary edema: Both have bilateral infiltrates and hypoxia. Key: PCWP normal in ARDS (<18), elevated in cardiogenic (>18). BNP low in ARDS.
★ Memory Trick
Acute dyspnea: "WHEEZES" — Wheeze (asthma/COPD/cardiac asthma), Heart failure, Embolism, Effusion, Zona (pneumothorax), Everything else, Sepsis/pneumonia BNP: "<100 rules OUT HF. >400 rules IN HF. 100–400 = clinical judgment." PE: "Normal CXR + hypoxia + tachycardia = PE until proven otherwise" Silent chest: "Quiet = Dangerous. Wheeze = air moving. Silence = NOTHING moving."
Tier 1
Differential D-2
Chronic Cough (>8 weeks) — The Big Four
Upper Airway Cough Syndrome · Asthma · GERD · ACE Inhibitor · Less Common Causes
★★★ PANCE Priority
The Four Most Common Causes of Chronic Cough
CauseKey FeatureDiagnosisTreatment
Upper Airway Cough Syndrome (UACS / Post-nasal drip)Sensation of drip down throat, throat-clearing, nasal congestion. Cough worse supine.Clinical; nasal exam shows cobblestoningIntranasal corticosteroids + antihistamine/decongestant
Cough-Variant AsthmaCough only — no wheeze, no dyspnea. Nocturnal. Triggers: cold, exercise, allergens.Normal spirometry → methacholine challenge (positive = >20% FEV1 drop at ≤4 mg/mL)ICS ± SABA; step-up per GINA
GERD-Related CoughPostprandial, worse lying down, associated heartburn (but may be silent GERD)Clinical; pH monitoring if unclear; empiric PPI trialPPI + lifestyle modification; may take weeks to improve
ACE Inhibitor-Induced CoughDry, tickling, persistent cough in any patient on ACEi (lisinopril, enalapril, etc.)Clinical — resolves within 1–4 weeks of stopping ACEiSwitch to ARB (same CV benefit, no cough). Do NOT rechallenge with ACEi.
Non-Asthmatic Eosinophilic Bronchitis (NAEB)Cough, eosinophilia on sputum cytology, normal spirometry, negative methacholineSputum eosinophils >3%; normal airway responsivenessICS — excellent response
Red Flags in Chronic Cough — Order Imaging
  • Hemoptysis — lung cancer, TB, bronchiectasis, PE (pulmonary infarction)
  • Weight loss + night sweats + upper lobe infiltrate — tuberculosis until proven otherwise
  • Smoker age >50 + new or changed cough — lung cancer workup (LDCT if meets screening criteria)
  • Hoarseness + dysphagia + cough — recurrent laryngeal nerve compression (mediastinal mass, apical lung tumor)
  • Immunocompromised + cough + bilateral infiltrates — PCP, fungal, atypical infection
⚑ Board Traps — Chronic Cough
  • ACE inhibitor cough is a class effect — ALL ACEi cause it, not just one agent. Switching to a different ACEi will not fix it. Switch to ARB.
  • Cough-variant asthma has a normal spirometry at rest — if you only order spirometry and it is normal, you have NOT ruled out asthma. Methacholine challenge is required.
  • GERD-related cough may have NO heartburn — silent GERD is a common board scenario. A patient with chronic cough and no obvious reflux symptoms may still have GERD as the cause.
  • Empiric treatment sequence for chronic cough: Stop ACEi first (if applicable) → treat UACS → treat asthma → treat GERD. Most cases resolve with sequential empiric therapy.
Tier 1
Differential D-3
Hemoptysis — Benign to Life-Threatening
Bronchitis · TB · Lung Cancer · PE · Bronchiectasis · Massive Hemoptysis
★★★ PANCE PriorityMassive Hemoptysis Emergency
Differential by Clinical Context
CauseClinical ClueKey Distinguishing Feature
Acute Bronchitis (Most Common)Young patient, URI prodrome, pink-tinged or blood-streaked sputum, self-limitedStreaky blood mixed with mucus; CXR normal; self-resolves
TuberculosisImmigrant, homeless, incarcerated, HIV; night sweats, weight loss, upper lobe cavitationUpper lobe infiltrate/cavitation; AFB smear and culture; IGRA positive
Lung CancerSmoker age >40; persistent hemoptysis; weight loss; new CXR mass; Pancoast featuresNew or enlarging mass on CXR/CT; central lesion (squamous/SCLC); PET-CT and biopsy
Pulmonary Embolism (Infarction)Pleuritic chest pain + dyspnea + sudden onset; infarction causes true hemoptysisHampton's hump (wedge-shaped pleural density); Wells score + CTPA
BronchiectasisChronic productive cough, recurrent pneumonias; CF, prior TB, immunodeficiencyCT: dilated bronchi ("tram-track" or "signet ring" sign); daily mucopurulent sputum
Mitral StenosisRheumatic heart disease, young woman, dyspnea, opening snap on examPink frothy sputum; elevated pulmonary venous pressure; echo confirms MS
Massive Hemoptysis (>300–600 mL/24h)Any etiology; airway compromise; tachycardia; patient drowning in own bloodAirway = priority. Position bleeding side DOWN. Intubate if necessary. Bronchial artery embolization (IR) is definitive. Surgery last resort.
⚑ Board Traps — Hemoptysis
  • Massive hemoptysis: position the bleeding lung DOWN — prevents blood from drowning the good lung. Lateral decubitus with affected side down.
  • PE-related hemoptysis = pulmonary infarction (not always present). Classic: pleuritic chest pain + hemoptysis + dyspnea in a high-risk patient. Don't be reassured by a negative initial workup — raise pre-test probability.
  • Any persistent hemoptysis in a smoker over 40 = lung cancer until proven otherwise — order CT chest regardless of CXR findings. CXR misses 20% of lung cancers.
  • TB hemoptysis: Can be massive due to Rasmussen aneurysm (dilated pulmonary artery adjacent to a TB cavity). Bronchial artery embolization is the intervention of choice.
Tier 1
Differential D-4
Obstructive vs Restrictive vs Mixed — PFT Pattern Recognition
FEV1/FVC · TLC · DLCO · Clinical Correlation · DLCO Subtypes
★★★ PANCE PrioritySpirometry-Only Trap
The Master PFT Framework
PatternFEV1/FVCFVCTLCDLCOClinical Examples
Obstructive<0.70 (or below LLN)Normal or ↓Normal or ↑ (air trapping)Low (emphysema) or Normal (asthma/bronchitis)Asthma, COPD, bronchiectasis, CF
RestrictiveNormal (≥0.70)↓<80% predicted (required for diagnosis)Low (ILD) or Normal (NM/chest wall)IPF, sarcoidosis, obesity, neuromuscular
Mixed↓↓↓VariableCombined emphysema + fibrosis, advanced sarcoidosis
Normal spirometry (possible asthma)NormalNormalNormalNormal or elevatedCough-variant asthma — methacholine challenge needed
DLCO — The Disease Discriminator
DLCO FindingMechanismDiagnoses
Low DLCO + Obstructive PFTAlveolar wall destruction → ↓ surface areaEmphysema (COPD). Distinguishes emphysema from chronic bronchitis (normal DLCO).
Low DLCO + Restrictive PFTFibrosis → thickened alveolar-capillary membraneIPF, sarcoidosis, hypersensitivity pneumonitis, CTD-ILD
Low DLCO + Normal spirometryVascular/capillary bed destruction without airway or parenchymal diseasePulmonary arterial hypertension, pulmonary embolism, anemia (corrected for Hgb)
Elevated DLCOIncreased pulmonary blood volume or intrapulmonary hemorrhagePulmonary hemorrhage syndromes (Goodpasture, polyangiitis), left-to-right shunt, polycythemia, obesity
Normal DLCO + Obstructive PFTAirway disease without alveolar destructionAsthma, chronic bronchitis — alveoli intact
Normal DLCO + Low spirometry (FVC only)Airway or chest wall/neuromuscular disease without gas exchange impairmentNeuromuscular disease, obesity (pseudo-restriction)
⚑ Board Traps — PFTs
  • Restriction CANNOT be diagnosed by spirometry alone. Low FVC + normal FEV1/FVC is suggestive but requires TLC <80% predicted (body plethysmography) to confirm. Low FVC also occurs from poor effort, obesity, or NM weakness.
  • Asthma can have a completely normal spirometry — normal FEV1/FVC at rest does not rule out asthma. Methacholine challenge is required when clinical suspicion is high.
  • DLCO is the key to separating emphysema from chronic bronchitis — both have obstructive spirometry. Emphysema = low DLCO. Chronic bronchitis = normal DLCO. This distinction appears on nearly every pulmonary exam.
  • Combined pulmonary fibrosis + emphysema (CPFE): Spirometry may look nearly normal (restriction and obstruction cancel each other) but DLCO is severely reduced. Do not be reassured by normal spirometry in a smoker with dyspnea and low DLCO.
★ Memory Trick
PFT hierarchy: "Ratio first, then FVC, then TLC, then DLCO" Emphysema vs Bronchitis: "E for Emphysema = Empty alveoli = low DLCO. B for Bronchitis = Big airways problem only = normal DLCO." Low DLCO alone (normal PFT): "Think vessels — PAH or PE" Elevated DLCO: "Hemorrhage into alveoli — blood absorbs CO"
Tier 1
Differential D-5
Pleural Effusion — Transudate vs Exudate vs Complicated
Light's Criteria · Albumin Gradient · pH Decision · RA vs Malignancy vs HF
★★★ PANCE PriorityDiuretic Light's Trap
Light's Criteria — Applied Decision Framework
Light's Criteria — Exudate if ANY ONE of Three Is Met
  • Pleural protein / Serum protein >0.5
  • Pleural LDH / Serum LDH >0.6
  • Pleural LDH >2/3 the upper limit of normal for serum LDH
  • If NONE met → Transudate. If ANY ONE met → Exudate.
Transudates vs Exudates — Clinical Differential
CategoryCommon CausesKey Distinguishing Feature
TransudateHeart failure (#1), cirrhosis, nephrotic syndrome, hypoalbuminemiaBilateral effusions + JVD + orthopnea = HF. Bilateral + ascites + jaundice = cirrhosis.
Exudate — InfectiousParapneumonic (simple or complicated), empyema, TB pleuritisFever + consolidation + effusion = parapneumonic. pH ≤7.2 = complicated → drain mandatory.
Exudate — MalignantLung cancer, breast, lymphoma, mesotheliomaLarge unilateral effusion + weight loss + smoking. Cytology positive in ~60%.
Exudate — InflammatoryRheumatoid arthritis, lupus, pancreatitis, PERA: lowest pleural glucose of any effusion (<30 mg/dL, sometimes near 0). Lupus: ANA in fluid. Pancreatitis: high amylase.
HF on diuretics (misclassified)HF being treated aggressivelyMeets Light's exudate criteria but clinical picture = HF. Check serum-pleural albumin gradient: >1.2 g/dL = transudate despite Light's. NT-proBNP >1500 in fluid = HF confirmed.
Solitary Pulmonary Nodule — PANCE Approach

PANCE tests the decision logic, not the Fleischner size thresholds:

  • Low-risk nodule (<6mm, incidental, non-smoker, no risk factors): Routine follow-up, no immediate CT
  • Intermediate-risk (6–8mm or any size with risk factors — smoker, age >35, prior cancer): CT chest in 3–6 months
  • High-risk / suspicious (>8mm, spiculated, growing): PET-CT → biopsy vs surgical resection
  • PANCE rule: New nodule + smoker + age >35 + upper lobe = workup. New nodule + young non-smoker + round smooth margins = likely benign, follow.

🩺 PANCE Pearl: Popcorn calcification = hamartoma (benign). Central calcification = old granuloma (benign). Eccentric/no calcification + spiculated = malignant until proven otherwise.

⚑ Board Traps — Pleural Effusion
  • Light's criteria misclassifies ~25% of diuretic-treated HF effusions as exudates. When clinical picture = HF but Light's says exudate → check serum-pleural albumin gradient. >1.2 g/dL = transudate.
  • Pleural fluid pH ≤7.2 = the most critical single test for determining drainage in parapneumonic effusions. This single value determines whether antibiotics alone will work.
  • RA effusion has the lowest glucose — near zero in some cases. This is a classic board fact used to distinguish RA from other causes of low pleural glucose.
  • Bilateral effusions first get treated medically (diuretics for HF) — thoracentesis is not the initial step for bilateral effusions in the appropriate clinical context. Unilateral or atypical = tap first.
  • Mesothelioma = asbestos exposure + large pleural effusion + pleural thickening + NO fever. History of asbestos work is the pivotal clue.
Tier 2
Differential D-6
Solitary Pulmonary Nodule — Malignant vs Benign
Solitary Pulmonary Nodule — PANCE Approach · Risk Stratification · Calcification Patterns · Growth Rate
★★ High Yield
Calcification Pattern — The Most Tested Feature
Calcification PatternImplicationCommon Cause
PopcornBenignHamartoma (most common benign lung tumor)
Central / Laminated / DiffuseBenignGranuloma (histoplasma, TB, coccidioides)
Target / Bull's-eyeBenignHistoplasmoma
Eccentric / Stippled / AmorphousIndeterminate — malignancy possibleCannot exclude lung cancer — further workup needed
No calcificationIndeterminateCT follow-up schedule based on nodule size, risk factors, and growth rate
High-Risk Features Requiring Aggressive Workup
  • Size >8 mm in high-risk patient — PET-CT and/or biopsy
  • Growth on serial CT — doubling time <400 days suggests malignancy
  • Spiculated margins — malignancy until proven otherwise (classic adenocarcinoma appearance)
  • Upper lobe location + smoker — higher malignancy risk regardless of size
  • Ground-glass opacity (GGO) nodule — adenocarcinoma spectrum (AIS → MIA → invasive). Slower growth but significant malignancy risk.
⚑ Board Traps — Pulmonary Nodule
  • Popcorn calcification = hamartoma = benign. No further workup needed. This is the one calcification pattern that definitively confirms benignity.
  • Spiculated nodule = malignancy until proven otherwise — irregular, stellate margins indicate local invasion into surrounding lung. This morphology overrides size criteria for workup.
  • A "stable" nodule is not automatically benign — stability must be demonstrated over 2 years on serial CT. Six months of stability is insufficient.
  • Low-risk patients (<35, never-smoker) with small smooth nodules can be observed; high-risk patients warrant more aggressive evaluation at smaller sizes.
Tier 1
Differential D-7
Pneumonia Differential — Typical vs Atypical vs Special Populations
CAP vs HAP · Typical vs Atypical · Immunocompromised · TB vs PCP vs Fungal
★★★ PANCE Priority
Typical vs Atypical Pneumonia — The Classic Distinction
FeatureTypical (Bacterial)Atypical ("Walking")
OnsetAbrupt, with rigorsGradual, prodrome 1–2 weeks
CoughProductive, purulent sputumDry, non-productive ("walking pneumonia")
CXRLobar or segmental consolidationBilateral diffuse, patchy, interstitial infiltrates
OrganismsS. pneumoniae (#1), H. influenzae, Moraxella, KlebsiellaMycoplasma (#1 in young adults), Chlamydophila, Legionella
TreatmentBeta-lactam (amoxicillin outpatient; ceftriaxone inpatient)Macrolide (azithromycin) or doxycycline or fluoroquinolone
Lab clueHigh WBC, elevated procalcitonin, positive Gram stainCold agglutinins (Mycoplasma), Legionella urine antigen, Chlamydia serology
Special Populations — The Board Favorites
PopulationPathogen to KnowKey Clinical Clue
HIV+ CD4 <200Pneumocystis jirovecii (PCP)Bilateral ground-glass infiltrates + dry cough + subacute onset + LDH elevated. Normal or near-normal CXR early. TMP-SMX first-line; add prednisone if PaO₂ <70.
Alcoholic / Poor dentitionAspiration pneumonia — anaerobes (Bacteroides, Peptostreptococcus)RLL (upright) or RUL posterior (recumbent aspiration); putrid sputum; lung abscess
COPD / smokerH. influenzae, Moraxella catarrhalis, S. pneumoniaeExacerbation + infiltrate; prior antibiotic exposure increases resistant organisms
Ohio/Mississippi ValleyHistoplasma capsulatumBird/bat droppings exposure; mediastinal lymphadenopathy; calcified granulomas
Southwest US (desert)Coccidioides immitisValley fever; arthralgias, erythema nodosum; "Valley fever" = Coccidioidomycosis
Pacific Northwest / Great LakesBlastomyces dermatitidisSkin lesions + lung disease; verrucous skin ulcers
Immunocompromised (neutropenia)Aspergillus fumigatusHalo sign on CT (ground-glass surrounding nodule); galactomannan antigen; treat with voriconazole
Legionella — The High-Yield Atypical
  • Classic patient: Older male, smoker, immunosuppressed, recent hotel/hospital exposure, contaminated water systems
  • Classic features: Severe CAP + hyponatremia + diarrhea + elevated liver enzymes + confusion (extrapulmonary features)
  • Diagnosis: Legionella urinary antigen (fast, detects serogroup 1 = 80% of cases). Sputum culture on BCYE agar.
  • Treatment: Fluoroquinolone (levofloxacin) or azithromycin — beta-lactams do NOT work (Legionella is intracellular)
⚑ Board Traps — Pneumonia
  • Metronidazole is NOT routinely added to CAP regimens — adding anaerobic coverage to community-acquired pneumonia increases mortality (IDSA 2019 guidelines). It is used for aspiration pneumonia/abscess, not standard CAP.
  • Legionella is NOT covered by beta-lactams — it is an intracellular pathogen. Macrolides or fluoroquinolones are required. A patient with severe CAP not responding to ceftriaxone alone should prompt consideration of Legionella.
  • PCP: normal or near-normal CXR early — bilateral GGO on CT is the classic finding. LDH is elevated (sensitive but not specific). Treat empirically in HIV+ with CD4 <200 and compatible presentation while awaiting bronchoscopy.
  • Aspiration pneumonia vs aspiration pneumonitis: Pneumonitis = chemical injury from acid, resolves without antibiotics in 24–48h. Pneumonia = bacterial superinfection, requires antibiotics. Location matters: right lower lobe (upright) or right upper lobe posterior segment (recumbent).
Module E · Comprehensive Board Pearls
Board Pearls — Organized by Domain
These pearls represent the exact clinical decision points most frequently tested on PANCE/PANRE pulmonary questions. Each pearl targets a specific mechanism the exam uses to separate passing from failing candidates.
Tier 1
Board Pearls — Obstructive Lung Disease
Asthma & COPD — High-Yield Decision Points
★★★ Highest Yield
  • SABA-only therapy is obsolete (GINA 2024). All asthma patients need ICS-containing therapy at every step. As-needed low-dose ICS-formoterol for mild asthma reduces exacerbations by ≥60% vs SABA alone.
  • LABA monotherapy is contraindicated in asthma (increases asthma-related death) but is appropriate in COPD. This distinction is tested every exam cycle.
  • Silent chest in asthma = impending respiratory failure, NOT improvement. No air movement = no wheeze. Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue = prepare for intubation.
  • IV magnesium sulfate 2g over 20 minutes is for severe asthma exacerbation not responding to bronchodilators. It relaxes bronchial smooth muscle via calcium antagonism.
  • Do NOT sedate the agitated asthmatic. Agitation = hypoxia, not anxiety. Sedation removes respiratory drive and precipitates arrest.
  • COPD O₂ target: SpO₂ 88–92%. High-flow O₂ suppresses hypoxic drive in CO₂ retainers → hypercapnic respiratory failure. LTOT target is not 95%+.
  • LTOT indication: PaO₂ ≤55 OR SpO₂ ≤88% at rest. Or PaO₂ 55–60 if pulmonary HTN, cor pulmonale, or polycythemia. SpO₂ 89–93% without additional risk factors does NOT meet criteria (LOTT trial).
  • COPD Gold Group B: dual bronchodilation (LAMA + LABA) is preferred first-line. ICS is not routinely added unless eosinophilia ≥300 or ≥2 exacerbations per year.
  • Roflumilast (PDE4 inhibitor): Add-on for GOLD Group E (severe, frequent exacerbations) with chronic bronchitis phenotype. Contraindicated in underweight patients (causes significant weight loss).
  • Alpha-1 antitrypsin deficiency: Young non-smoker or minimal smoker with early-onset panlobular (basilar) emphysema + liver disease. Serum A1AT level + phenotype. Augmentation therapy if indicated.
Tier 1
Board Pearls — Pulmonary Infections
CAP · TB · PCP · Atypical Organisms · Drug Toxicity
★★★ Highest Yield
  • Inpatient CAP standard regimen: ceftriaxone + azithromycin. Fluoroquinolone monotherapy is an alternative, not first-line. Metronidazole is NOT added to CAP (increases mortality).
  • BCG vaccination causes false-positive TST but NOT IGRA. Always use IGRA in BCG-vaccinated patients from endemic countries. HIV+ lowers TST threshold to ≥5mm.
  • Active TB vs LTBI distinction: Active = symptoms + CXR abnormality + positive AFB smear/culture. LTBI = positive test + no symptoms + normal CXR. RIPE therapy for active; INH × 9 months (or 3HP) for LTBI.
  • RIPE drug toxicity — memorize all four: Rifampin = orange body fluids (benign) + CYP450 inducer (lowers many drug levels including OCP, warfarin). Isoniazid = peripheral neuropathy (give B6/pyridoxine) + hepatotoxicity. Pyrazinamide = hyperuricemia (gout). Ethambutol = optic neuritis (monitor color vision monthly).
  • PCP prophylaxis: TMP-SMX when CD4 <200. Treat active PCP with TMP-SMX IV. Add prednisone if PaO₂ <70 mmHg or A-a gradient >35 (reduces inflammation, improves survival).
  • Legionella: beta-lactams do NOT work. Intracellular pathogen requires macrolide or fluoroquinolone. Urine antigen is the fastest diagnostic test. Classic clue: CAP + hyponatremia + diarrhea.
  • Geographic fungi — memorize the map: Ohio/Mississippi Valley = Histoplasma. Southwest desert = Coccidioides ("Valley Fever"). Pacific Northwest/Great Lakes = Blastomyces. Immunocompromised anywhere = Aspergillus (halo sign on CT → voriconazole).
  • CURB-65 score ≥2 = hospitalization recommended for CAP. CURB-65: Confusion, Urea >7, RR ≥30, BP <90/60, age ≥65. Score 0–1 = outpatient; 2 = inpatient; 3–5 = consider ICU.
Tier 1
Board Pearls — ILD, Sarcoidosis & Pulmonary Hypertension
IPF · Sarcoid · PAH · WHO Groups · Cor Pulmonale
★★★ Highest Yield
  • IPF treatment: antifibrotics (nintedanib or pirfenidone) slow FVC decline but do not reverse fibrosis. Corticosteroids do NOT help IPF and may worsen prognosis. The PANTHER trial showed triple immunosuppression (AZA + NAC + prednisone) increased mortality — abandoned.
  • UIP pattern on HRCT = IPF diagnosis without biopsy in the right clinical context (older male smoker, Velcro crackles, clubbing). Honeycombing + traction bronchiectasis in subpleural basal distribution = UIP.
  • Löfgren syndrome = clinical diagnosis of sarcoidosis, no biopsy required. Triad: bilateral hilar lymphadenopathy + erythema nodosum + ankle periarthritis. Excellent prognosis; 85–90% spontaneous resolution.
  • Serum ACE is NOT diagnostic for sarcoidosis — it is neither sensitive nor specific enough. Tissue biopsy showing non-caseating granulomas is required (unless Löfgren syndrome).
  • Sarcoidosis cardiac involvement: complete heart block or VT in a young patient — always consider sarcoid when cardiac conduction disease occurs in a young patient with bilateral hilar adenopathy.
  • WHO Group 3 (lung disease) pulmonary hypertension: PAH-specific drugs are NOT indicated — they worsen V/Q mismatch. Treat underlying lung disease + LTOT. PAH-specific drugs are for WHO Group 1 only (after right heart catheterization).
  • Right heart catheterization is required to definitively diagnose PAH — mean PAP >20 mmHg at rest + PCWP ≤15. Echo estimates RVSP but cannot replace RHC for diagnosis or drug decisions.
  • Cor pulmonale (RV failure from lung disease): JVD + peripheral edema + RV heave + P2 loud + right-sided S3. Treat with O₂ (most important), diuretics cautiously, treat underlying lung disease. NOT with vasodilators (worsen V/Q mismatch).
Tier 1
Board Pearls — PE, Pleural Disease & Pneumothorax
Wells Criteria · Fibrinolytics · Light's Criteria · pH Rule · Tension PTX
★★★ Highest YieldMultiple Emergency Traps
  • Wells ≤4 = PE unlikely → D-dimer first. Wells >4 = PE likely → CTPA directly. Negative D-dimer with low pre-test probability excludes PE. D-dimer is a rule-out test only.
  • PERC rule: if ALL 8 criteria met in a patient with <15% pre-test probability → no further PE workup. PERC is not applied to intermediate or high pre-test probability patients.
  • Massive PE (SBP <90): systemic fibrinolytics (alteplase 100mg IV over 2 hours) if no contraindications. Anticoagulation alone is insufficient. IVC filter does NOT treat the hemodynamic crisis.
  • DOACs are first-line for PE treatment with two exceptions: antiphospholipid syndrome (warfarin only — TRAPS trial) and mechanical heart valves (warfarin only).
  • Apixaban and rivaroxaban need NO parenteral bridge. Dabigatran and edoxaban require 5–10 days of LMWH before starting. This distinction is tested.
  • Duration of anticoagulation: Provoked PE (surgery, immobility) = 3 months. Unprovoked = minimum 3 months, discuss extended therapy. Cancer-associated = LMWH or DOAC (rivaroxaban or apixaban) indefinitely while cancer active.
  • Light's criteria misclassifies ~25% of diuretic-treated HF effusions as exudates. Corrective test: serum-pleural albumin gradient >1.2 g/dL = transudate. NT-proBNP >1500 in pleural fluid = HF confirmed.
  • Pleural fluid pH ≤7.2 is the single most important decision point for parapneumonic drainage. This value mandates chest tube placement. Antibiotics alone fail at this pH.
  • RA pleural effusion has the lowest glucose (<30 mg/dL, sometimes near 0). Classic board fact separating RA from other low-glucose exudates.
  • Tension pneumothorax = clinical diagnosis — DO NOT get CXR. Absent breath sounds + tracheal deviation AWAY from affected side + hemodynamic collapse = needle decompression at 2nd ICS, MCL immediately. Then chest tube. Seconds matter.
  • Supplemental O₂ accelerates PTX reabsorption by nitrogen washout — give high-flow O₂ even in normoxic patients with pneumothorax.
  • Any patient on positive-pressure ventilation with a pneumothorax requires chest tube. Observation is NOT safe — risk of rapid tension PTX with every breath.
Tier 1
Board Pearls — Lung Cancer & Screening
USPSTF Criteria · Cell Types · Paraneoplastic Syndromes · SVC Syndrome
★★★ Highest Yield
  • USPSTF 2021 lung cancer screening (LDCT): age 50–80, ≥20 pack-years, currently smoking or quit within 15 years. All three must be met. Stop at age 80 or if quit >15 years ago.
  • Adenocarcinoma (#1 most common overall): Peripheral, non-smokers, women, EGFR/ALK/KRAS mutations → targeted therapy. Associated with hypertrophic osteoarthropathy (clubbing). Ground-glass opacity on CT.
  • Squamous cell (#1 central): Hilar/central, cavitates, smoker. Paraneoplastic = PTHrP-mediated hypercalcemia (PTH suppressed). Pancoast tumor (superior sulcus) = Horner syndrome + brachial plexopathy + shoulder/arm pain.
  • SCLC paraneoplastics — memorize all: SIADH (hyponatremia, most common), ectopic ACTH (Cushing's), Lambert-Eaton myasthenic syndrome (weakness improves with repetition — OPPOSITE of MG), anti-Hu antibodies (encephalitis). SCLC = chemo only, no surgery.
  • Lambert-Eaton vs Myasthenia Gravis: Lambert-Eaton = proximal weakness that IMPROVES with repetition (calcium channel antibodies), VGCC antibodies. MG = weakness that WORSENS with repetition (AChR antibodies). SCLC = Lambert-Eaton. Thymoma = MG.
  • SVC syndrome: Facial swelling + arm swelling + headache + dilated neck/chest veins. SCLC is the #1 cause. Urgent radiation ± stenting. Elevate head of bed. Steroids for symptom relief.
  • Horner syndrome from Pancoast tumor: Ptosis + miosis + anhidrosis (ipsilateral). Apical lung cancer invading the superior cervical sympathetic chain. Always order chest CT with apical views when Horner is found.
  • Large cell carcinoma is a diagnosis of exclusion — when no glandular (adeno), squamous, or small cell differentiation is identified. Associated with gynecomastia (β-hCG). Peripheral, poorly differentiated, aggressive.
Tier 1
Board Pearls — Pulmonary Pharmacology
Contraindications · Drug Interactions · Monitoring · Key Distinctions
★★★ Highest YieldDrug Trap Targets
  • LABA contraindication in asthma: LABA monotherapy without ICS is absolutely contraindicated. Always combine with ICS. In COPD, LABA monotherapy is acceptable.
  • ICS side effects: Oral candidiasis (prevent by rinsing mouth after use) and dysphonia. NOT systemic immunosuppression at standard doses. High-dose ICS can suppress HPA axis.
  • Theophylline (methylxanthine): Narrow therapeutic index. Toxicity: nausea, tremor, tachycardia, seizures. Level 10–15 μg/mL therapeutic; >20 = toxic. Many drug interactions (macrolides, fluoroquinolones increase levels). Rarely used now.
  • Rifampin is a potent CYP450 inducer — reduces levels of warfarin, oral contraceptives, methadone, many HIV antiretrovirals, azole antifungals. Counsel patients on alternative contraception during TB treatment.
  • Isoniazid requires pyridoxine (B6) supplementation — prevents peripheral neuropathy (especially in elderly, malnourished, diabetics, pregnant women, alcoholics). Standard dose: 25–50 mg/day.
  • Sildenafil/tadalafil (PDE5 inhibitors) for PAH: Cannot be combined with nitrates (severe hypotension). Used for WHO Group 1 PAH. Not for Group 3 (lung disease) — worsens V/Q mismatch.
  • Macrolides for COPD (azithromycin 250mg daily): Reduces exacerbation frequency in GOLD Group E patients. Risk: QT prolongation (check EKG baseline), hearing loss, Mycobacterium avium complex (MAC) resistance. Not for current smokers (higher risk of respiratory events).
  • Systemic corticosteroids in COPD exacerbation: Prednisone 40mg × 5 days. No benefit beyond 5 days (REDUCE trial). No taper needed for short courses. Reduces treatment failure and hospital stay.
  • TMP-SMX in PCP: dose is weight-based (15–20 mg/kg/day TMP component). Prophylaxis dose: one double-strength tablet daily. Adverse effects: rash (Stevens-Johnson in HIV), hyperkalemia, nephrotoxicity.
Fast Review
10 Rapid-Fire Pulmonary Clinical Pearls
Clinical Emergency List
10 "Don't Miss" Pulmonary Emergencies
1. Tension Pneumothorax
Clinical diagnosis — never wait for CXR. Absent breath sounds + tracheal deviation AWAY from affected side + hemodynamic collapse. Needle decompress immediately (14–16G, 2nd ICS, MCL), then chest tube. Seconds count — this kills in minutes. On mechanical ventilation: suddenly ↑ peak pressures + ↓ O₂ + ↓ BP = tension PTX.
2. Massive Pulmonary Embolism
SBP <90 + confirmed PE on CTPA or echo. Systemic thrombolysis (alteplase 100mg IV over 2h) if no contraindications. Anticoagulation alone is insufficient. Surgical embolectomy if lytics fail or are contraindicated. Mortality without treatment approaches 60%. Start anticoagulation simultaneously with thrombolytics.
3. Status Asthmaticus (Life-Threatening Exacerbation)
Silent chest + rising PaCO₂ + SpO₂ <90% despite bronchodilators. IV magnesium 2g + continuous nebulized albuterol + ipratropium + IV steroids. Prepare for intubation. Permit permissive hypercapnia on vent. Do NOT sedate the agitated patient — agitation = hypoxia. Heliox for refractory bronchospasm.
4. COPD Exacerbation with Hypercapnic Respiratory Failure
PH <7.35, PaCO₂ rising, increasing work of breathing. BiPAP is first-line — NOT intubation. BiPAP reduces intubation rate, mortality, and ICU stay. Failure of BiPAP or contraindication (coma, aspiration risk, hemodynamic instability) → intubate. Set vent to prevent auto-PEEP (prolonged expiratory time, low RR).
5. Massive Hemoptysis
Coughing >500–600 mL blood/24h or any hemoptysis causing hemodynamic instability. Most common causes: TB, bronchiectasis, lung cancer, aspergilloma. Protect the airway first — position affected side DOWN. Bronchoscopic localization + endobronchial tamponade → bronchial artery embolization (IR) → surgery if all else fails. ICU admission.
6. Acute Respiratory Distress Syndrome (ARDS)
Bilateral infiltrates + P/F ratio <300 + not from HF + onset within 7 days of insult. Lung-protective ventilation: Tidal volume 6 mL/kg IBW, plateau pressure <30 cmH₂O, PEEP titration. Prone positioning for P/F <150. Neuromuscular blockade for severe ARDS. Avoid fluid overload. No proven pharmacotherapy.
7. Empyema
Frank pus in pleural space — always drain, no exceptions. Antibiotics alone will not resolve empyema. Chest tube insertion mandatory. If loculated: intrapleural fibrinolytics (tPA + DNase) or VATS decortication. pH <7.2 in parapneumonic effusion = complicated → drain before frank empyema develops. Do NOT procrastinate — undrainable loculation develops rapidly.
8. Epiglottitis (Upper Airway Emergency)
Adult: Hib, Streptococcus. "Tripod position" + drooling + muffled voice + severe odynophagia + "thumbprint sign" on lateral CXR. DO NOT do direct laryngoscopy without airway control ready. Controlled intubation in OR with ENT/anesthesia present. IV antibiotics (ceftriaxone). Racemic epinephrine while preparing airway.
9. Superior Vena Cava (SVC) Syndrome
Facial plethora + bilateral arm edema + dilated neck/chest wall veins + dyspnea. Most common cause = lung cancer (especially SCLC) or lymphoma. CT chest with IV contrast confirms. Urgent radiation (non-SCLC) or chemo (SCLC) + steroids. Endovascular stenting for rapid symptom relief. NOT an immediate surgical emergency, but biopsy before treatment if possible.
10. Miliary Tuberculosis
Hematogenous dissemination — bilateral "millet seed" nodules on CXR (1–2mm). Fever + night sweats + weight loss + multiorgan failure. Can cause TB meningitis (LP for AFB), bone/joint TB, hepatic involvement, Addison's disease (adrenal TB). Initiate RIPE therapy immediately — do not await culture results if clinical suspicion high. Consider steroids if concurrent TB meningitis.
Chapter Summary
Top 20 Pulmonary Board Traps
From your source material + confirmed. These are the PANCE-winning distinctions.
20 Traps · All Domains
1
Asthma — GINA 2024
SABA-only treatment is NO LONGER recommended for asthma at any severity. All patients need ICS-containing therapy. As-needed ICS-formoterol is preferred for mild asthma.
2
Asthma — LABA Safety
LABA monotherapy is CONTRAINDICATED in asthma (increases asthma-related death). Must always combine with ICS. LABA alone is acceptable in COPD — not in asthma.
3
Asthma — Silent Chest
Silent chest in acute asthma = impending respiratory failure, NOT improvement. No wheezing = no air movement. More dangerous than audible wheezing.
4
Asthma — PaCO₂ Trap
Normal or rising PaCO₂ in severe asthma = respiratory muscle fatigue and impending arrest. Patients should be hyperventilating (low CO₂). "Normal" CO₂ = catastrophically abnormal.
5
Asthma vs COPD — Spirometry
Asthma = reversible obstruction (≥12% + ≥200mL FEV1 improvement post-BD). COPD = irreversible. This is the single most important spirometric distinction on boards.
6
PFTs — Restriction Rule
Restrictive disease CANNOT be diagnosed by spirometry alone. Low FVC with normal FEV1/FVC = suggestive only. TLC <80% predicted (body plethysmography) is required to confirm.
7
PFTs — DLCO
DLCO differentiates emphysema (low) from chronic bronchitis (normal) and asthma (normal/high). Both emphysema and bronchitis are obstructive — DLCO is the key differentiator.
8
COPD — ICS Rule
ICS monotherapy is NEVER appropriate in COPD. Always combine with a long-acting bronchodilator. ICS in COPD increases pneumonia risk — use only when clearly indicated (eos ≥300, frequent exacerbations).
9
COPD — Eosinophils Guide ICS
Blood eosinophil count guides ICS use in COPD: ≥300 cells/μL = likely benefit. <100 = unlikely benefit. 100–300 = consider based on exacerbation frequency.
10
COPD — LTOT
LTOT benefits severe resting hypoxemia (SpO₂ ≤88%) only — NOT moderate hypoxemia. LOTT trial: no benefit for SpO₂ 89–93% or exercise-only desaturation. O₂ target 88–92%.
11
COPD — O₂ Target
Target SpO₂ 88–92% in COPD — excessive O₂ suppresses hypoxic drive in CO₂ retainers and worsens hypercapnia. Do NOT target 95–100%.
12
COPD — BiPAP
NIV (BiPAP) is first-line for COPD exacerbation with respiratory failure — reduces intubation, mortality, and ICU stay. Reserve intubation for BiPAP failure or contraindication.
13
CAP — Fluoroquinolones
Fluoroquinolones are NOT first-line for CAP. Reserve for β-lactam/macrolide intolerance. Risks: C. diff, tendon rupture, QT prolongation, resistance. β-lactam + macrolide is preferred inpatient.
14
CAP — Antibiotic Duration
3-day antibiotic course is sufficient for hospitalized CAP if stability criteria met by day 3 (afebrile, HR <100, RR <24, SBP ≥90, SpO₂ ≥90%, able to eat). Longer courses are NOT superior.
15
CAP — Aspiration
Do NOT add anti-anaerobic coverage (metronidazole, clindamycin) for aspiration pneumonia — associated with 5–6% higher mortality. Standard CAP antibiotics are adequate per 2019 ATS/IDSA guidelines.
16
PE — D-Dimer Rule
D-dimer is a RULE-OUT test only for PE — do NOT order in high-probability patients (Wells >4, go straight to CTPA). A positive D-dimer does NOT diagnose PE. It is highly sensitive but not specific.
17
PE — DOACs First-Line
DOACs are first-line for PE treatment — warfarin is no longer preferred. Exceptions: antiphospholipid syndrome (warfarin only — TRAPS trial) and mechanical heart valves (warfarin only).
18
PE — Thrombolysis Threshold
Systemic thrombolysis for MASSIVE PE only (SBP <90 mmHg). NOT for submassive PE unless hemodynamic deterioration occurs despite anticoagulation.
19
Pleural — pH Rule
Pleural fluid pH ≤7.2 = complicated parapneumonic effusion requiring chest tube drainage. The most critical test for determining need for drainage. Antibiotics alone will NOT resolve it.
20
PTX — Clinical Diagnosis
Tension pneumothorax = clinical diagnosis — immediate needle decompression, do NOT wait for CXR. Absent breath sounds + tracheal deviation away from PTX + hemodynamic collapse = needle decompress now.
Quick-Scan Reference — Numbers That Win Points
ASTHMA REVERSIBILITY
≥12% AND ≥200mL FEV1↑ post-BD
COPD O₂ TARGET
SpO₂ 88–92%
LTOT if SpO₂ ≤88%
IV Mg ASTHMA
2g IV over 20 min
(severe, refractory)
PLEURAL DRAINAGE
pH ≤7.2 → chest tube
Empyema → always drain
PE THROMBOLYSIS
Alteplase 100mg / 2h
Massive only (SBP <90)
TB RIPE DURATION
2 months RIPE
+ 4 months RI = 6 months
LUNG CA SCREENING
Age 50–80, ≥20 pack-yrs
Current or quit <15 yrs
TST THRESHOLDS
≥5mm: HIV/contacts
≥10mm: high-risk groups
≥15mm: anyone
⬡ Closing Statement
"Pulmonary on the PANCE rewards the student who has internalized the exceptions. The silent chest that looks calm. The CO₂ that looks normal. The SABA-only inhaler that looks like enough. The tension PTX that you should never wait to image. These are the moments that define board performance — and clinical practice. Master the traps, and the right answer becomes obvious."
— Rajiv Choudhary, MD, MPH
PA Pulmonary Medicine Bootcamp Syllabus
Rajiv Choudhary, MD, MPH
● LIVE STRIP25mm/s
⚑ Board Trap